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The purpose of this thesis was to study the rate and extent of aggregation of 
human and bovine insulin in bulk and in the presence of either polystyrene microspheres 
with different surface chemistries or liposomes of different composition. Insulin 
aggregation was followed by turbidimetry, Fourier transform infrared spectroscopy 
(FTIR), and dynamic light scattering. The Congo red assay was used to corroborate the 
presence of amyloid deposits and transmission electron microscopy (TEM) was used to 
analyze the morphology of the amyloid deposits.  
Our results show that not all the surfaces shortened the lag time. On the other 
hand, most surfaces had an impact (either significant or minute) on the growth rate of 
both insulins. Faster nucleation was observed at all times for both insulins when 
incubated at 60 ˚C vs. 37 ˚C, 230 rpm. Furthermore, considerable secondary structure 
changes (from random coils and α-helices to β sheets and turns) in both insulins during 
fibrillation were observed.  
Both, human and bovine insulin exhibited analogous fibril morphologies (i.e. 
similar length, width, and structure) when treated under the same conditions in the 
presence and in the absence of surfaces with the exception of incubation at 37 ˚C, 230 
rpm stirring for 55 hours. In addition, when human and bovine insulin were subjected to 
mechanical stresses the fibrils appear “fragmented” and hence their size is smaller when 
compared to insulin that has not been agitated. Bovine insulin fibrils are longer and 
thinner under these incubation conditions (37 ˚C, 230 rpm) than human insulin fibrils. 
Incubation temperatures were different between agitated insulin (37 ˚C) and non-agitated 
insulin (60 ˚C). It is also noticeable that at 60 ˚C larger fibrils formed at longer incubation 
times, for both insulins. The width of the fibrils ranged between 10 to 20 nm, there is not 
a noticeable dependence/correlation between fibril length and width for human or bovine 
insulin. On the other hand, based on the obtained images, the statistical analysis, and in 
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Amyloid fibrils are ordered aggregates of peptides or proteins that are associated 
with many diseases such as Alzheimer’s, Parkinson’s, and Huntington’s diseases, type 2 
diabetes mellitus, etc. (Nilsson, 2004). Amyloid diseases are apparently unconnected; 
however, intermolecular secondary structure (mainly β-sheet) is present in all amyloid 
aggregates. A number of factors that contribute to the formation of amyloid fibrils 
include, but are not limited to, temperature, protein concentration, pH, ionic strength, and 
amino acid sequence. There are three criteria that define a protein aggregate as an 
amyloid fibril: fibrillar morphology, green birefringence upon staining with Congo Red, 
and β-sheet secondary structure (Nilsson, 2004).  
We have chosen insulin to study amyloid fibril formation in bulk and in the 
presence of interfaces because (i) insulin is a well-studied protein that is known to 
develop structurally similar cross-β-sheet plaques to those found in other amyloid-
forming proteins (ii) insulin is readily available in large amounts at a reasonable price and 
(iii) its amino acid sequence is highly conserved from species to species, which facilitates 
the study of minute changes in amino-acid sequence on fibrillation. Insulin is a glucose 
regulatory hormone composed of two polypeptide chains: the A-chain, which consists of 
21 amino acids, and the B-chain, which consists of 30 amino acids. Insulin has a helical 
native structure, with its two polypeptide chains linked together by two interchain and 
one intra-chain disulfide bonds (Brange et al., 1997). In solution, this protein is found as 
an equilibrium mixture of monomers, dimers, tetramers, and hexamers (which vary 
according to pH and concentration, among other factors) (Klunk et al., 1989). 
Insulin is mainly stored as a zinc-coordinated hexamer while zinc-free insulin is a 
dimer at low protein concentration over the pH 2-8 range, changing to a tetramer at 
protein concentrations above 1.5 mg/ml (Brange et al., 1987). Nielsen et al. (2001b) 
studied the effect of pH on the association of human and bovine insulin. At pH 7.4 insulin 
is hexameric and it dissociates upon decreasing the pH. At pH 3 insulin exists as a 
tetramer, at pH 2.0 is monomeric in acetic acid and at pH 1.6 insulin is dimeric. Despite 
the fact that insulin aggregation has been extensively studied, the differences in the 
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aggregation behavior between proteins from different species have not been deeply 
investigated. The aggregation behavior of human and bovine insulin in vitro in bulk and 
at solid/liquid interfaces is explored in this thesis.  
The amino acid sequences of human and bovine insulin are different in positions 
8 and 10 of the A-chain and in position 30 of the B- chain. Threonine (Thr), a polar 
amino acid in position 8 of the A chain in human insulin is substituted in bovine insulin 
by alanine (Ala), a nonpolar amino acid. Isoleucine (Ile), a nonpolar amino acid in 
position 10 of the A chain of human insulin, is substituted in bovine insulin by valine 
(Val), a nonpolar amino acid as well. Finally, threonine (Thr), in position 30 of human 
insulin, is substituted in bovine by alanine (Ala). 
Formation of insulin fibrils is a physical process in which non-native molecules 
interact with each other to form linear, biologically inactive aggregates (Brange et al., 
1997). In vitro insulin fibril formation has been shown to result in the formation of 
insoluble aggregates which are rich in β-sheet structures (Nielsen et al., 2001a). 
Numerous studies, reviewed below, have shown that once insulin has been exposed to 
elevated temperatures, mechanical stresses, organic solvents, and low pH is prone to 
fibrillation. 
It has been shown by Waugh (1940, 1941) that the formation of insulin fibrils 
occurs before precipitation and that the heat treatment does not completely modify the 
globular nature of the insulin molecule. Waugh later demonstrated that heat precipitation 
consists of three steps: 1) nucleation (formation of active centers), 2) growth (elongation 
of these centers to fibrils), and 3) precipitation/equilibrium (floccule formation) (Waugh, 
1946a; Waugh 1946b; Waugh et al., 1953). These steps involve interactions between 
nonpolar side chains (hydrophobic interactions) (Nielsen et al., 2001a; Bryant et al., 
1993; Waugh, 1946a). Although nucleation appears to need temperatures above ambient, 
the growth into fibrils can happen at ambient or lower temperatures and, depending on 
the conditions, the growth leads to long fibrils or to shorter fibrils with a propensity to 
assemble radially to spherulites with precipitation as the result (Waugh et al., 1953; 
Waugh, 1957). 
The concentration dependence of bovine insulin aggregation was studied by 
Sluzky et al. (1991). They concluded that the aggregation process is kinetically 
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controlled, with rates of aggregation proportional to protein concentration. Their study 
also demonstrated the importance of mechanical stresses by showing that an increase in 
the agitation rate decreased the initial lag phase and that the rate of aggregation became 
steeper. 
Nielsen et al. (2001a) investigated the effect of insulin concentration, pH, ionic 
strength, agitation, anions (i.e. 1-anilinonaphthalene-8-sulfonic acid (ANS)), the use of 
denaturants (such as urea), stabilizers (like sucrose) and seeding of fibrils on the kinetics 
of fibril formation. In agreement with Sluzky et al. (1991), they found that higher insulin 
concentrations lead to shorter lag times and faster growth. Their studies also 
demonstrated that shorter lag times and faster growth of fibrils are attained at acidic pH 
compared to neutral pH, while an increase in ionic strength yielded shorter lag times and 
slower growth. According to their results, there was no clear connection between the rate 
of fibril elongation and ionic strength. Furthermore, they concluded that strong agitation 
(960 rpm) was the dominant effect on the kinetics of insulin aggregation. The presence of 
the anion (ANS) and the stabilizer (sucrose) increased the lag time while the presence of 
the denaturant (urea) decreased it. Finally, they showed that the addition of seeds 
eliminated the lag time. 
Waugh (1946a) observed the formation of small spherulites produced in 2% 
insulin/1% sodium chloride solution in hydrochloric acid at pH 1.8 incubated at 100 ˚C 
for 3 minutes. According to him, the structure of the spherite (as it was called then) is one 
of statistical orientation of the constituent fibrils. He also suggested that a new fibril 
entering the association has to diffuse into the region of the growing spherite and become 
correctly oriented. We obtained spherical aggregates by the method (see description in 
Appendix A) of Burke and Rougvie (1972). Figure 1.1 shows amyloid spherulites by 
themselves and amyloid spherulites coexisting with amyloid fibrils obtained by this 
method which is similar to that of Waugh. All the micrographs were obtained from the 








Figure 1.1. Negative staining scanning electron images of bovine insulin fibrils and 
spherulites obtained by the method of Burke and Rougvie (1972). (a) and (b) may 
suggest that fibril formation and random coil aggregation occur at the same time 
under certain conditions. (c) and (d) illustrate the presence of spherulites. The scale 




The presence of solid/liquid or liquid/air interfaces affects the formation of fibrils. 
The following studies have shown that the physicochemical nature of the surface plays a 
critical role in amyloid fibril formation and impacts the kinetics, the size and the shape of 
amyloid aggregates and fibrils. Sluzky et al. (1991) observed an increase in bovine 






(1997) suggested that insulin denatures and aggregates at the liquid/air interface 
generated during vigorous agitation (Aggregation of proteins at the liquid/air interface is 
a well-known phenomenon). The effect of roughness and surface wettability on human 
insulin fibrillation was studied by Nayak et al. (2008) by atomic force microscopy and 
UV-vis absorption spectroscopy. They noticed a decrease of the lag phase in the presence 
of different polymeric surfaces such as regenerated cellulose, polyethylene, and poly 
ethersulfone). They concluded that the nucleation rate increased with increasing surface 
roughness and decreasing surface wettability. The effect of lipid/water interfaces on 
protein fibrillation has also been investigated (Sharp et al., 2002; McLaurin et al., 2002). 
Sharp and coworkers utilized lipid-coated polystyrene surfaces (such as 1,2-dioleoyl-3-
trimethylammonium propane (DOTAP, cationic headgroup) and 1,2-dioleoyl-sn-
glycerol-3-[phosphor-rac-(1-glycerol)] (DOPG, anionic headgroup)) to study surface 
denaturation and amyloid fibril formation of bovine insulin. Their results show that both 
negatively (containing DOPG) and positively (containing DOTAP) charged liposomes 
accelerate the rate of unfolding and of beta sheet formation. DOPG containing liposomes 
were less effective than DOTAP containing ones. McLaurin et al., (2002) explored the 
role of cholesterol in bulk in Aβ40/42 fibrillogenesis. They observed fibril formation in 
the case of Aβ40 but not with Aβ42, which forms amorphous aggregates.  
The molecular mechanism of amyloid fibril formation is not fully understood. 
Several mechanisms that may lead to the formation of aggregates are under discussion. 
The more widespread one is nucleated polymerization. In this mechanism an uncommon 
event leads to the formation of a nucleus (frequently considered to be a small oligomer, 
but it could be an unusual monomer conformation). Once this nucleus forms, it leads to 
the development of the formation of a fibril. Protofilaments (thought to consist of two β-
sheets running in parallel) can wrap up around each other to form protofibrils or mature 
fibrils, which are generally considered to be composed of two to six protofilaments.  
It is now believe that protein folding does not involve a sequence of steps from an 
specific partially folded state to another one but rather it would involve a stochastic 
search of the several conformations accessible to a polypeptide chain (Dobson et al., 
1998; Wolynes et al., 1995). People have suggested that aggregation of insulin occurs by 
exposing the hydrophobic residues that are usually buried within the protein’s structure, 
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this destabilizes the protein and aggregation begins. Mass spectrometry of amyloid 
insulin fibrils has confirmed that the disulfide bonds of the native protein are retained in 
the amyloid structure (Nettleton et al., 1998). 
 It has been suggested by Ahmad et al. (2003) that the first step in insulin 
fibrillation is the formation of a non-native, partially unfolded, monomeric intermediate. 
Nielsen et al. (2001b) proposed a model for insulin fibril formation in which the 
formation of amyloid fibrils starts with hexamer/trimer/dimer units followed by the 
dissociation of these units into the monomer which has to unfold to some extent to form 
the intermediate necessary to produce the nucleus from which amyloid fibrils can grow. 
Vestergaard et al. (2007) suggested that the main elongation mechanism of insulin fibrils 
consists of the addition of oligomers to the growing fibril. They demonstrated that the 
growth rate is proportional to the number of oligomers and that the amount of monomers 
in solution is close to zero during the later phases of fibril formation.  
A left-handed helical twist has been described for all of the amyloid fibrils for 
which the hand has been confirmed such as human calcitonin (hCT) peptide hormone, 
and human amylin (Bauer, et al., 1995, Goldsbury et al., 1997). Based on this evidence 
and on the fact that the twist between β-sheets and β-strands is also left-handed, a model 
for the protofilaments’ twist was suggested by Jimenez et al. (2002) in which the 
protofilaments must be left-handed and must follow the overall twist of the fibril. In 
contrast to previous models based on a β-coil structure (Blake & Serpell, 1996). Jimenez 
and coworkers also indicated that the β-sheets in amyloid protofilaments have to 

















Human and bovine insulin were used without further purification. Table 2.1 is a 




Table 2.1. Insulin sources. 
Insulin 
(source) 
Vendor Catalog No. Lot No. Zinc content (%) 
(1) 
Human 
SACF Biosciences 91077C 10L918 Unknown 
(2) SIGMA I2643 096K03811V 0.4 
(3) SIGMA I2643 SLBC1253V 0.4 
(4) 
Bovine 
Sigma-Aldrich 15500 019K17765V 0.5 
(5) SIGMA I1882 099K8702 0.5 




The latexes used were: (1) monodisperse polystyrene (PS) (average particle 
diameter: 107 nm, concentration: 2.64 w/v %) latex, (2) polystyrene hydroxylate (PS-
OH) (average particle diameter: 193 nm, concentration: 2.63 w/v %), (3) polystyrene 
carboxylate (PS-COOH) (average particle diameter: 107 nm, concentration: 2.57 w/v %), 
and (4) polystyrene amino (PS-NH2) (average particle diameter: 108 nm, concentration: 
2.63 w/v %). All the latexes were purchased from Polysciences, Inc. Warrington, PA.  
Five different types of liposomes were prepared. Lipids were dissolved at a 
concentration of 30 mg/ml in tert-butyl alcohol. The lipids, cholesterol (≈99%), L-α- 
phosphatidylcholine from egg yolk (≈99%), L-α- phosphatidylethanolamine from egg 
yolk (≈98%), L-α-phosphatidyl-DL-glycerol, and L-α- phosphatidyl-L-serine from 
glycine max (soybean) were purchased from Sigma (St. Louis, MO) and used without 
further purification. Nanopure water was used in all experiments. The compositions of 
the liposomes are shown in Table 2.2.   
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Table 2.2. Composition of liposomes. 
Liposome Composition Abbreviation 
1 80%/20%      PC/PS C: Cholesterol 
2 20%/80%      PC/C PC: Phosphatidylcholine 
3 80%/20%      PC/C PE: Phosphatidylethanolamine 
4 2:2:1:1          C/PC/PG/PE PG: Phosphatidylglycerol 
5 10:5:7.5:16   PC/PE/PS/C PS: Phosphatidylserine 





Congo red dye (C6277, Lot# MKBB0292) was purchased from Sigma-Aldrich, 








2.2.1. Preparation of Insulin Fibrils. All solutions were freshly prepared before 
each experiment. The solution consisted of 25 mM HCl, 100 mM NaCl adjusted to pH 
1.6 (insulin is dimeric under these conditions). This solution was filtered through a 
Whatman 0.45 μm polysulfone membrane filter and then filtered again through a 
Whatman 0.2 μm polyethersulfone membrane filter. Stock protein solutions were 
prepared in this buffer at a concentration of 2 mg/ml. For bulk insulin samples, the 
required amount of sample was withdrawn from the stock solution and no further sample 
preparation was performed.  
For insulin samples in the presence of surfaces, enough solution was withdrawn 
from the stock solution to prepare two samples (i.e. duplicates) but only one sample was 
prepared and then this sample was split in two to obtain “identical duplicates”. All 
samples consisted of 1 to 2 ml (depending on the cuvette size) of 2 mg/ml insulin at a 
surface concentration of 12 cm
2
/mg of insulin, with the exception of the control samples 
which contained only human or bovine insulin (also with duplicates). The samples were 
then transferred to disposable poly(methyl)methacrylate square cells. Two different 
incubation conditions were used for turbidimetry, FTIR, and dynamic light scattering 
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(DLS): 1) 37 ˚C at 230 rpm up to 55 hours, and 2) 60 ˚C for 4 to 6 hours. For TEM, the 
previous incubation conditions were used plus incubation at 60 ˚C for 40 hours. The 
samples were removed from the incubator at appropriate time intervals for analysis and 
were immediately placed back in the incubator.  
2.2.2. Preparation of Liposomes. Liposomes were prepared by the freeze drying 
method (Li and Deng, 2004). 20 mg of lipid was dissolved in 1 ml of tert-Butyl Alcohol 
(TBA). Then, 150 mg of sucrose was dissolved in 1 ml of water. These two solutions 
were mixed at a volume ratio between 1:1 and 1:2. After mixing the solution remained 
optically clear. The mixture was further sonicated for less than a minute in order to assure 
proper mixing. The solution was then filtered through a Whatman 0.22 μm 
polyethersulfone membrane filter. The sample was then freeze-dried. After drying, the 
sample was stored in the freezer. The dried solid was dissolved in the appropriate amount 
of buffer before using. 
2.2.3. Turbidity. The formation of fibrils was followed by monitoring the 
turbidity of the sample at 600 nm (OD600). The absorbance at 600 nm was measured 
using a Hitachi U-2900 Double-Beam UV/Vis spectrophotometer (Hitachi High 
Technologies America, Inc). Measurements were taken at multiple times. 
2.2.4. Fourier Transform Infrared (FTIR) Spectroscopy. Analysis of the 
samples was performed in a Thermo Scientific Nicolet 6700 FTIR. At proper time 
intervals, the sample was gently shaken to distribute fibrils uniformly in the microtube 
before withdrawing aliquots of 8-10 μl. The sample was placed on a CaF2 window and 
left to dry under the hood (drying took no more than 2 minutes). The sample chamber of 
the FTIR was purged with dry, CO2 free, air for a few minutes before and after loading 
the sample. A scan of the CaF2 window (without sample) was used as the background 
(Fandrich and Dobson, 2002; Kong and Yu, 2007; Nilsson, 2004). A total of 32 scans per 
sample were taken at a resolution of 4 cm
-1
. A few runs were done with native insulin in a 
KBr pellet and the results were identical to those obtained by placing a solution of the 
hormone on the CaF2 window and measuring after evaporation of the water. 
2.2.5. Dynamic Light Scattering (DLS). The experiments were performed on a 
fiber-optic quasi-elastic light scattering (FOQELS) instrument from Brookhaven 
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Instruments Corp (Brookhaven). Measurements were done at 830 nm, at a 135.70° 
scattering angle, at 37 ˚C or 60 ˚C. Samples were measured for 30 seconds. 
2.2.6. Congo Red Histological Dye Binding to Insulin Fibrils. The method of 
Klunk et al. (1989) was used. A stock solution of Congo red was prepared by dissolving 7 
mg of the dye in 1ml of a buffer solution consisting of 0.15 M sodium chloride and 5 mM 
potassium phosphate, adjusted to pH 7.4. This solution was filtered twice through a 
Whatman 0.2-μm polyethersulfone membrane filter. 1 ml of the described buffer was 
added to a disposable poly(methyl)methacrylate square cell and the Hitachi U-2900 
Double-Beam UV/Vis spectrophotometer (Hitachi High Technologies America, Inc) was 
zeroed with this solution between 400 and 700 nm at room temperature. Next, 5 μl of the 
Congo red dye stock solution was added to the cell, a spectrum was recorded between 
400 and 700 nm. Lastly, 10 µl of the protein sample was added to the same cell and 
another spectrum was recorded between 400 and 700 nm. After each addition, the cuvette 
was tilted a few times to mix its contents. Congo red tests were performed on all samples 
at the end of each experiment. A maximal spectral difference at 540 nm indicated the 
presence of amyloid fibrils.  
2.2.7. Imaging by Transmission Electron Microscopy (TEM) and Scanning 
Electron Microscopy (SEM). The morphology of insulin fibrils under different 
conditions was examined with a FEI Tecnai F20 transmission electron microscope with 
an accelerating voltage of 120 kV or with a Helios NanoLab 600 Dual Beam 
(FIB/STEM) FEI Microscope operated under STEM mode at 30kV. A drop of water-
diluted suspension of insulin fibrils (100 ml of the 2 mg/ml solution were diluted with 
300 ml of water) was placed on a 200-mesh formvar copper grid (EMS, USA) and 
allowed to dry for 3 minutes. The excess solution was gently wicked off. Subsequently, 
the grid was negatively stained with a 5% (w/v) aqueous solution of uranyl acetate and 
left to dry for 3 minutes. Once again, the excess solution was gently wicked off. 
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The rate and extent of aggregation of human and bovine insulin in bulk and in the 
presence of either polystyrene microspheres with different surface chemistries or 
liposomes of different compositions were studied. Insulin aggregation was followed by 
turbidimetry, Fourier transform infrared spectroscopy (FTIR), and dynamic light 
scattering (DLS). The Congo red assay was used to corroborate the presence of amyloid 
deposits and electron microscopy was used to analyze the morphology of the amyloid 
deposits.  
Due to a scarcity of both insulins during this study different vendors and batches 
of human and bovine insulin were utilized in this work. This should be kept in mind 
when looking at the results since different batches may yield different results. The insulin 
source (a number) is given for each and every result from which the details of the insulin 
used (vendor information, catalog number, etc) can be found on Table 2.1.  
 
3.1. MONITORING THE PROGRESS OF AGGREGATION BY TURBIDITY 
Figures 3.1 to 3.8 show the kinetics of fibril formation followed by absorbance at 
600 nm. Each data set is the average of two runs. The aggregation kinetics shows a 
pronounced lag phase that is followed by a sigmoidal increase (aggregate growth) and 
ends on a plateau which corresponds to the formation of mature fibrils. These features are 
usually assigned to a nucleation-dependent aggregation mechanism that consists of a 
nucleation, growth and precipitation/equilibrium phases (Jarrett and Lansbury, 1993). 
The results are presented first for human and bovine insulin in bulk followed by 
insulin in the presence of liposomes and polystyrene beads (incubation conditions: (1) 60 
˚C (Figures 3.1 – 3.6) and (2) 37 ˚C and 230 rpm (Figures 3.1, 3.7 and 3.8). The graphs 
are shown in accordance with the way the experiments were run, i.e. for the first 
experiments (and graphs) a set of bulk insulin solutions was prepared per surface. For the 
later experiments (and graphs) a single bulk insulin solution was prepared for the entire 
run.  
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The lag times and the apparent rate constants of both insulins in bulk and in the 
presence of surfaces can be found in Tables 3.1 and 3.2, and 3.3 respectively.  
When incubated at 60 ˚C, the lag times of human and bovine insulin in bulk are 
3.2 and 1.7 hr (sources 1 and 3) and 1.0 and 2.1 hr (sources 4 and 6),  respectively. The 
lag times of human and bovine insulin, when incubated at 37 
o
C and 230 rpm,  are 4.0 
and 11.0 hr, respectively (sources 2 and 6) (Figure 3.1, Table 3.1). However, under both 
incubation conditions, the growth rate is faster for bovine insulin than for human insulin. 
Furthermore, the higher the temperature the shorter the lag time and the faster the growth 
rate occurs.  
 
 















































Figure 3.1. Fibril formation of human and bovine insulin in bulk incubated at 60 ˚C 
followed by absorbance at 600 nm. (a): insulin species were human insulin from 
source 1 (●), human insulin from source 3 (○), bovine insulin from source 4 (▲) and 
bovine insulin from source 6 (Δ) Incubation at 37 ˚C and 230 rpm (b): insulin 
species were human insulin from source 2 (●) and bovine insulin from source 6 (▲). 












1 2.39 0.58 4 
3 4.73 2.44 6 
37 ˚C and 230 rpm 
2 7.05 13.31 6 
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Figure 3.2. Fibril formation of human insulin in bulk and in the presence of 
liposomes incubated at 60˚ C followed by absorbance at 600 nm. Human insulin 
(source 1): in bulk (●) and in the presence of liposome s (○).  (a) liposome 1 (80/20 
PC/PS), (b) liposome 2 (20/80 PC/C), (c) liposome 3 (80/20 PC/C), (d) liposome 4 







Figure 3.2 shows that the only liposomes that have an impact on the lag time of 
human insulin are liposomes 4 (2:2:1:1 C/PC/PG/PE) and 5 (10/5/7.5/16 PC/PE/PS/C). 
From panel d, the lag time of human insulin in bulk (source 1) is 0.67 hr while in the 
presence of liposome 4 is 0.60 hr. The lag time of human insulin in bulk is 0.75 hr and in 
the presence of liposome 5 is 0.67 hr (panel e). Nonetheless, all the liposomes accelerate 
the aggregation of human insulin with liposome 3 (80/20 PC/C) having the greatest 
impact.  
The data shown in Figure 3.3 shows that liposomes affect the overall kinetics of 
bovine insulin (source 4) more than that of human insulin (source 1, Figure 3.2). It is also 
noticeable that liposome 3 (80/20 PC/C) shortens the lag time and accelerates the growth 
rate of bovine insulin more than any other liposome (1.10 hr vs. 0.67 hr in bulk, panel c). 
Liposomes 1 (80/20 PC/PS) and 5 (10/5/7.5/16 PC/PE/PS/C) have a minor effect on the 
lag time and the growth rate of bovine insulin while liposomes 2 (20/80 PC/C) and 4 
(2:2:1:1 C/PC/PG/PE) reduced the lag time significantly. The lag time for bovine insulin 
in bulk is 0.95 hr (panel b) and 0.85 hr (panel d) whereas in the presence of liposomes 2 
and 4 the lag time is 0.67 hr, panels b and d respectively. 
 Both, human (panel a) and bovine (panel b) insulin from sources 3 and 6 (Figure 
3.4) have slower kinetics than the insulins from sources 1 and 4, respectively. Liposome 
2 had the biggest impact on the lag time (2.05 hr) and growth rate of human insulin; 
conversely, this liposome had the least impact on the lag time (1.85 hr) and growth rate of 
bovine insulin. Liposomes 3 (80/20 PC/C) and 6 (50/50 PC/C) affected the lag time of 
human insulin to the same extent (2.50 hr) but liposome 6 causes a faster growth rate. For 
bovine insulin, liposomes 3 and 6 had the same lag time (1.75 hr); in addition, their 
growth rates were almost identical.   
Figure 3.5 shows the aggregation kinetics of human and bovine insulin (sources 1 
and 4) in the presence of polystyrene (PS) beads. The lag time of human insulin in the 
presence of all polystyrene beads is the same (1.75 hr) as in bulk (panel a); however, the 
growth rates are different: PS-COOH causes the fastest growth rate followed by PS-NH2 
and PS-OH.  
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Figure 3.3. Fibril formation of bovine insulin in bulk and in the presence of 
liposomes  incubated at 60˚ C followed by absorbance at 600 nm. All insulin species 
were from source 4. Bovine insulin: in bulk (●) and in the presence of liposome 
surface (○). Results shown are for: liposome 1 (80/20 PC/PS) (a), liposome 2 (20/80 
PC/C) (b), liposome 3 (80/20 PC/C) (c), liposome 4 (2:2:1:1 C/PC/PG/PE) (d) and 
liposome 5 (10/5/7.5/16 PC/PE/PS/C) (e). The absorbance was normalized on a scale 




An interesting phenomenon occurs in the growth rates of human insulin in bulk 
and in the presence of PS: the growth rate is faster for human insulin in bulk until it 
reaches 50% of the absorbance then the growth rate of human insulin in the presence of 
PS becomes faster than that of human insulin in bulk. All the polystyrenes, but PS-NH2, 





COOH (0.85 hr) and PS-OH (0.75 hr). The lag time is the same for bovine insulin in bulk 
and bovine insulin in the presence of PS-NH2 (0.70 hr). The growth rates of bovine 
insulin followed the same trends as the lag times: i.e., from slowest to fastest: PS, PS-
COOH and PS-OH. Bovine insulin in bulk and in the presence of PSNH2 have the same 
growth rate until they reach about 40% of the absorbance but they behave quite 
differently after that point.  
 















































Figure 3.4. Fibril formation of human and bovine insulin in bulk and in the 
presence of liposomes incubated at 60 ˚C followed by absorbance at 600 nm. All 
human insulin species were from source 3 and all bovine insulin was from source 6. 
Results shown are for human insulin, panel (a) and bovine insulin, panel (b): in bulk 
(●), in the presence of: liposome 2 (20/80 PC/C) (○), liposome 3 (80/20 PC/C) (▲) 
and liposome 6 (50/50PC/C) (Δ). The absorbance was normalized on a scale from 



















































Figure 3.5. Fibril formation of human and bovine insulin in bulk and in the 
presence of polystyrene beads incubated at 60 ˚C followed by absorbance at 600 nm. 
All human insulin species were from source 1 and all bovine insulin was from source 
4. Results shown are for human insulin, panel (a) and bovine insulin, panel (b): in 
bulk (●), in the presence of: PS (○), PS-OH (▲), PS-COOH (Δ) and PS-NH2 (□). 
The absorbance was normalized on a scale from zero to one. 
 
 The growth rate of bovine insulin in bulk seems to overshoot until it reaches the 
elongation phase while the growth rate of bovine insulin in the presence of PS-NH2 
continues to increase linearly until it reaches the elongation phase. 
As previously discussed, human and bovine insulin from sources 3 and 6 have 
slower aggregation kinetics than the insulins from sources 1 and 4, respectively. Figure 
3.6 shows that the lag time of human insulin (panel a) in bulk (3.20 hr) was not affected 
by PS-NH2 (3.20 hr) while PS-COOH shortened the lag time (2.95 hr). The growth rates 
in both polystyrenes were faster than human insulin in bulk with PS-COOH being 




while that of bovine insulin in the presence of PS-COOH (slowest growth rate) and PS-
NH2 (fastest growth rate) is 2.10 hr. 
 
 















































Figure 3.6. Fibril formation of human and bovine insulin in bulk and in the 
presence of polystyrene beads incubated at 60 ˚C followed by absorbance at 600 nm. 
All human insulin species were from source 3 and all bovine insulin was from source 
6. Results shown are for human insulin, panel (a) and bovine insulin, panel (b): in 
bulk (●), in the presence of: PS-COOH (○) and PS-NH2 (Δ). The absorbance was 




Figure 3.7 shows the aggregation kinetics of human (panel a) and bovine (panel b) 
insulin (sources 2 and 6) incubated at 37 ˚C and 230 rpm in the presence of liposomes. 
The lag time of human insulin in bulk is 4.00 hr while that of bovine insulin in bulk is 
11.0 hr. All the liposomes but 6 (50/50 PC/C) had an impact on the lag time of human 




presence of liposomes 2 (20/80 PC/C) and 3 (80/20 PC/C) produced lag times of 2.00 hr 
and 3.50 hr, respectively. The growth rates follow the same trends as the lag times with 
liposome 5 causing the fastest rates followed by liposomes 2, 6, 4 and lastly human 
insulin in bulk.  















































Figure 3.7. Fibril formation of human and bovine insulin in bulk and in the 
presence of liposomes incubated at 37 ˚C and 230 rpm followed by absorbance at 
600 nm. All human insulin species were from source 2 and all bovine insulin was 
from source 6. Results shown are for human insulin, panel (a) and bovine insulin, 
panel (b): in bulk (●), in the presence of: liposome 2 (20/80 PC/C) (○), liposome 3 
(80/20 PC/C) (▲), liposome 5 (10:5:7.5:16 PC/PE/PS/C) (Δ) and liposome 6 
(50/50PC/C) (□). The absorbance was normalized on a scale from zero to one. 
 
All the liposomes but 2 (20/80 PC/C) affected the lag time of bovine insulin. 
Insulin has the shortest lag time (3.00 hr) in the presence of liposome 3 it has the same 
lag time in the presence of liposomes 5 and 6 (3.50 hr). The growth rates show the same 




insulin in bulk and in the presence of liposome seem to be faster than those of human 
insulin.  
Figure 3.8 shows the aggregation kinetics of human (panel a) and bovine (panel b) 
insulin (sources 2 and 6) incubated at 37 ˚C and 230 rpm in the presence of polystyrene  
 















































Figure 3.8. Fibril formation of human and bovine insulin in bulk and in the 
presence of polystyrene beads incubated at 37 ˚C and 230 rpm followed by 
absorbance at 600 nm. All human insulin species were from source 2 and all bovine 
insulin was from source 6. Results shown are for human insulin, panel (a) and 
bovine insulin, panel (b): in bulk (●), in the presence of: PS-COOH (○) and of PS-
NH2 (Δ). The absorbance was normalized on a scale from zero to one. 
 
 
beads. The lag time of human insulin in bulk is 4.00 hr while that of bovine insulin in 
bulk is 11.0 hr. PS-COOH eliminated the lag phase for both insulins. The lag time of 




The growth rates of bovine insulin in bulk and in the presence of liposome are faster than 
those of human insulin. Table 3.2 contains a summary of the obtained lag times. 
 
 
Table 3.2. Lag time of human and bovine insulin in the presence of surfaces. 
60 ˚C 
 Human Bovine 
Surface used 
 Lag Time (hr)  Lag Time (hr) 
Source Bulk Surface Source Bulk Surface 
Liposome 1 1 1.52 1.23 4 1.22 2.49 
Liposome 2 1 1.52 1.27 4 1.10 0.85 
Liposome 3 1 1.72 1.31 4 1.28 0.87 
Liposome 4 1 1.34 1.09 4 1.27 0.88 
Liposome 5 1 1.28 1.11 4 1.30 1.21 
PS 1 2.39 2.54 4 0.58 1.26 
PS-OH 1 2.39 2.12 4 0.58 1.11 
PS-NH2 1 2.39 2.16 4 0.58 0.96 
PS-COOH 1 2.39 2.03 4 0.58 1.17 
Liposome 2 3 4.74 3.54 6 2.44 2.27 
Liposome 3 3 4.74 4.03 6 2.44 1.93 
Liposome 6 3 4.74 3.73 6 2.44 1.96 
PS-NH2 3 4.74 4.80 6 2.44 2.51 
PS-COOH 3 4.74 4.75 6 2.44 ---- 
37 ˚C and 230 rpm 
Liposome 2 2 7.05 5.09 6 13.31 12.95 
Liposome 3 2 7.05 9.50 6 13.31 5.21 
Liposome 5 2 7.05 0.00 6 13.31 5.25 
Liposome 6 2 7.05 3.92 6 13.31 3.06 
PS-NH2 2 7.05 5.24 6 13.31 5.18 




The previous results, Figures 3.1 (panel a) to 3.6, indicate that when human and 
bovine insulin, in bulk and in the presence of surfaces, are incubated at 60 ˚C, they 
follow, to some extent, the same aggregation mechanism: a lag phase (first stage of the 
fibrillation process in which the nuclei is formed, preceding the detection of fibrils), a 
growth (elongation) phase and an equilibrium (or precipitation) phase. 
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Table 3.3.  Apparent aggregation rate constant of human and bovine insulin. 
60 ˚C 
 Human Bovine 
Surface used 
 kapp  (1/hr)  kapp   (1/hr) 
Source Bulk Surface Source Bulk Surface 
Liposome 1 1 5.43 5.51 4 9.87 12.00 
Liposome 2 1 5.43 5.32 4 10.15 8.64 
Liposome 3 1 4.26 4.99 4 9.67 7.17 
Liposome 4 1 5.19 4.64 4 12.84 8.83 
Liposome 5 1 6.63 7.28 4 9.50 11.87 
PS 1 4.54 8.06 4 3.11 7.61 
PS-OH 1 4.54 6.15 4 3.11 11.08 
PS-NH2 1 4.54 7.97 4 3.11 15.11 
PS-COOH 1 4.54 8.14 4 3.11 11.51 
Liposome 2 3 4.13 2.80 6 6.56 7.92 
Liposome 3 3 4.13 3.16 6 6.56 6.49 
Liposome 6 3 4.13 3.17 6 6.56 8.01 
PS-NH2 3 4.13 8.26 6 6.56 11.48 
PS-COOH 3 4.13 9.61 6 6.56 --- 
37 ˚C and 230 rpm 
Liposome 2 2 0.19 0.31 6 0.86 1.00 
Liposome 3 2 0.19 0.27 6 0.86 0.49 
Liposome 5 2 0.19 0.20 6 0.86 0.38 
Liposome 6 2 0.19 0.20 6 0.86 0.27 
PS-NH2 2 0.19 0.24 6 0.86 0.38 




The lag times of both insulins incubated at 60 ˚C vary from insulin to insulin, 
even within the same batch: in some instances the lag time of human insulin from source 
1 is faster than that of bovine insulin from source 4 but in some cases the opposite is true. 
The presence of “seeds” is likely to have caused this problem. Nonetheless, regardless of 
the insulin source and the lag times, the aggregation rates for bovine insulin are, for the 
most part, faster than those of human insulin. One can say that while the formation of the 
“active nucleus” (i.e. the lag time) varied from insulin to insulin, the elongation (growth 
phase) of such nucleus is faster for bovine insulin than for human insulin. 
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Figures 3.1 (panel b), 3.7 and 3.8 show that the aggregation of human and bovine 
insulin possibly follows the same mechanism irrespective of the incubation conditions 
(with a few exceptions). The lag phases are indeed longer for both insulins when the 
incubation temperature is lower. Shorter lag times for human insulin as compared to 
bovine insulin are evident but once again, the aggregation rates of bovine insulin are 
faster than those of human insulin indicating that while the formation of the “active 
nucleus” (i.e. the lag time) is faster for human insulin, the elongation (growth phase) of 
such nucleus is faster for bovine insulin.  
A few exceptions regarding the sigmoidal shape (and hence the reaction 
mechanism) are evident for human and bovine insulin when incubated at 37 ˚C and 230 
rpm. Such exceptions occur to human insulin in the presence of liposome 5 (10:5:7.5:16 
PC/PE/PS/C) (Figure 3.7) and to both insulins in the presence of PS-COOH (Figure 3.8). 
Under these conditions (37 ˚C and 230 rpm) and in the presence of such surfaces, the lag 
time is completely eliminated changing the shape of the curve. Such processes are 
commonly encountered when “seeding” takes place. Seeding (heterogeneous or 
homogeneous) often occurs at concentrations above the critical concentration and the 
nucleation (i.e. lag time) phase is bypassed by the introduction of an external nucleus or 
seed (a seed provides a template on which further insulin molecules can assemble to 
create a nucleus) (Jarrett and Lansbury, 1993). As a result of seeding, the lag time is 
eliminated and a first-order growth process takes place (Naiki and Nakakuki, 1996). In 
our case, more likely the surfaces used (liposome 5 and PS-COOH) acted as seeds, 
serving as a template for the insulin molecules to further assemble into insulin fibers. 
Another explanation of this phenomenon is the combination of the surface that acted as a 
seed along with the mechanical stresses (230 rpm) that the insulin was subjected to while 
being incubated (37 ˚C). It is worth noting that agitation increases the contact of insulin 
with air.  
The lag times of bovine insulin are plotted vs. the lag time of human insulin in 
Figure 3.9.  It is obvious that the lag times of bovine insulin are shorter than the lag times 
of human insulin when the hormones are incubated at 60  
o
C (Panel (a)).  The data at 37 
o
C are inconclusive.  The apparent rate constants of bovine insulin fibrillation are plotted 
vs. the apparent rate constants of human insulin in Figure 3.10.    Both panels show that 
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the rate constants for the fibrillation of bovine insulin are larger than the ones of human 
insulin irrespective of the incubation conditions.   
The “Oosawa Model” is the simplest feasible kinetic model describing a 
nucleation–elongation polymerization (Oosawa and Asakura, 1975). This model applies 
when the nucleus (least stable species) is in thermodynamic (unfavorable) equilibrium 
with the monomeric protein. For this type of aggregation processes, the fibril mass should 
at all times be proportional to t
2
 (i.e. a parabolic time pathway) at the beginning of the 
reaction, with essentially no lag phase. Moreover, a critical protein concentration must 
exist for the nucleation to take place. In the case of insulin fibrillation, this type of model 
is excluded due to the time dependence (clearly incompatible with a t
2
 behavior) at the 
beginning of the kinetics, i.e. the lag phase. Nonetheless, this mechanism has been widely 
used to describe amyloid fibrillation processes (Jarrett and Lansbury, 1992; Naiki and 
Nakakuki, 1996; Nielsen et. al, 2001a).  
The downhill polymerization or irreversible polymerization mechanism (a 
generalization of Oosawa’s classical-nucleation polymerization model) has also been 
used to describe insulin aggregation (Librizzi and Rischel, 2005; Grudzielanek et al. 
2005). This mechanism is different from the nucleation-dependent process in that the 
nucleation is not considered the rate-limiting step. Instead, they argue that earlier 
structural phases cause the lag phase (the generation of sufficient amounts of native 
monomeric protein or the initial unfolding event of the native species). Flyvbjerg et al. 
(1996) used this mechanism effectively to model the kinetics of tubulin polymerization. It 
has been suggest by Wang et al. (2010) that regardless of the chosen mechanism, several 





Figure 3.9. Lag time of bovine vs. human insulin.  (a) Incubation at 60 
o
C and (b) 
Incubation at 37 
o


































































Figure 3.10. Apparent rate constant of bovine vs. human insulin.  (a) Incubation at 
60 
o
C and (b) Incubation at 37 
o

































































Sluzky et al. (1992) showed that bovine insulin aggregates faster (2 days) in the 
presence of solid Teflon as opposed to bovine insulin in the presence of much more 
hydrophilic glass beads (no aggregation was observed for more than a week). Their 
incubation conditions were 37 ˚C and 160 rpm at insulin concentration of 0.6 mg/ml. 
They also suggested that insulin stability could be increased by minimizing unfavorable 
contacts between the hormone and hydrophobic surfaces.   
Nielsen et al. (2001b) conducted insulin aggregation studies with human insulin, 
bovine insulin and insulin mutants at various conditions, including incubation at 60 ˚C, 
pH 1.6 at insulin concentrations of 2 mg/ml. They concluded that the initial oligomeric 
state of the insulin has a major impact on the kinetics of nucleation, as reflected in the 
different lag times. All of their kinetic results (obtained from ThT fluorescence 
measurements) displayed a sigmoidal curve. They also concluded that bovine insulin is 
the fastest fibrillating native species under all their incubation conditions, including that 
at pH 7.4 and 37 ˚C in which bovine insulin is in its stable hexameric conformation. They 
claimed that substitution of Thr to Ala in position A8 in bovine insulin plays an important 
role for the greater propensity of bovine insulin to form fibrils. Ala
A8
 is located on the 
surface of the monomer of bovine insulin, and it has been suggested that the presence of 
this hydrophobic residue instead of Thr in human insulin might lead to the greater 
fibrillation tendency of bovine insulin. Lastly, their results suggest that insulin fibril 
formation, at least the initial nucleation, is primarily driven by hydrophobic interactions. 
A model for insulin fibrillation was proposed by them in which the formation of a 
partially folded intermediate is the precursor for associated species on the pathway to 
fibril formation.  
Nayak et al. (2008) studied the effect of different surfaces such as hydrophilic 
regenerated cellulose and hydrophobic poly(tetrafluoroethyle) (PTFE) on the aggregation 
of human insulin (at a concentration of 2mg/ml) incubated at 65 ˚C. They concluded that 
no matter what surface is used, they always tend to induce faster nucleation (i.e. shorter 
lag times), unless they are purposely designed with inhibitory chemistries. In addition, 
they claimed that the growth rates of formation of fibrils are not significantly affected by 
the presence of the surfaces. Their conclusions and our findings are somewhat different. 
In our case, not all the surfaces accelerated the lag time (this is more evident for both 
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insulins incubated at 60 ˚C). On the other hand, most surfaces had an impact (either 
significant or minute) on the growth rate of both insulins.  
 
3.2. FOURIER TRANSFORM  INFRARED SPECTROSCOPY  
FTIR was used to study the secondary structure changes of both insulins in bulk 
and in the presence of surfaces during fibrillation. An attempt was made to run 
turbidimetry and FTIR studies simultaneously but the sampling time of FTIR is much 
longer than that of turbidimetry when several samples are processed at once. The changes 
in secondary structure with respect to time are presented in the following tables (Tables 
3.4 through 3.15). The time is corresponds to the time elapsed when the sample was 
removed and not the time of the measurement. Fibrillation likely continued at room 
temperature and in the absence of stirring.  Figure 3.11 is a representation of the time 
evolution of the FTIR spectra (amide I region) of human insulin during fibril formation at 
60 ˚C. 



























Figure 3.11. Time evolution of the FTIR spectra (amide I region) of human insulin 
(source 2) during fibril formation at 60 ˚C. Samples were collected before heating (0 
min) and at numerous times during heating.   
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Before heating (time 0) human insulin, the amide I band is located at 1656.3 cm
-1
. 
The shape and the location of the band are consistent with the presence of mostly helical 
and/or disordered structures. Heating the solution at 60 ˚C and for 95 min causes a shift 
in the amide I region toward lower frequencies and the appearance of a minute shoulder 
are evident (Figure 3.11). The shift of the band implies the presence of a higher amount 
of disordered structure and the shoulder of a small amount of β-sheet structure. After 155 
minutes, new bands have emerged between 1,627 and 1665 cm
-1 
which indicate the 
presence of intermolecular β–sheet and β–turn structures. 
 Tables 3.4 to 3.15 show the secondary structure percentages obtained from the 
FT-IR spectra of human and bovine insulin in bulk and in the presence of surfaces under 
both incubation conditions (60 ˚C and 37 ˚C, 230 rpm). The reported values are averages 
of two experiments. Unfortunately, the time frames of the experiments for both insulin 
types are not the same. Nonetheless, a few time frames are similar and interesting 
information may be inferred from the data.  
 The secondary structures of both insulins incubated at 60 ˚C (sources 2 and 6) in 
bulk before heating (time 0) are very similar (Table 3.4). After approximately one hour, a 
considerable increase in α-helix content occurs in both insulins (88.7% and 84.3%). 
However, at longer times (125 and 120 min), a sharp decrease of α-helices and random 
coils takes place and a sharp increase of β-sheets occurs. It is also noticeable that after 
120 minutes bovine insulin is richer than human insulin in β-sheet content (72.1 vs. 
60.0%). 
Before incubation at 37 ˚C and 230 rpm (Table 3.5), human insulin (source 1) in 
bulk contains more random coils (43.4%) than bovine insulin (33.7%) (source 6); on the 
other hand, human insulin contains no β-sheets. After 17 hours, human insulin still has no 
β-sheets but bovine insulin has reached its maximum (70.1%); on the other hand, human 
insulin still contains a high amount of random coils (42.2%) while bovine insulin has 
none. After 45 hours, the amount of α-helix decreased in human (48.5%) and bovine 
(50.4%) insulin. The amount of β-turn and β-sheet is 14.8% and 44.3% and 21.9% and 




Table 3.4. Secondary structure percentage of human and bovine insulin in bulk 
incubated at 60 ˚C. 
  
























32.7 5.3 49.4 10.0 2.7 0 
0.0 3.7 88.7 6.8 0.9 35 
0.0 2.6 86.3 7.4 3.7 65 
6.9 4.5 54.2 0.4 34.1 95 
10.9 1.4 13.3 14.3 60.0 125 








33.0 3.7 49.9 7.5 6.0 0 
0.0 6.6 84.3 6.3 2.9 60 
2.3 4.6 0.3 20.8 72.1 120 
0.6 4.9 1.2 21.2 72.1 180 
0.6 3.4 1.4 21.2 73.4 240 
 
 
Table 3.5. Secondary structure percentage of human and bovine insulin in bulk 
incubated at 37 ˚C and 230 rpm. 
  























 43.4 0.0 48.5 8.1 0.0 0 
42.2 2.9 47.3 7.6 0.0 17 
0.0 0.0 91.9 6.0 2.1 25 
0.0 0.0 88.1 5.3 6.6 36 








33.7 2.3 50.4 9.6 4.0 0 
0.3 3.7 12.7 16.1 67.1 10 
0.0 2.5 12.4 15.0 70.1 17 
0.0 2.6 5.6 22.0 69.8 24 
0.0 2.7 6.1 21.7 69.4 36 




The secondary structure of both insulins incubated at 60 ˚C (sources 2 and 6) in 
the presence of liposome 2 (20/80 PC/C) before heating (time 0) is very similar (Table 
3.6). As time increases (65 and 60 min) a considerable increase in α-helices (85.1%) and 
the loss of random coils occur in human insulin but not in bovine insulin whose 
secondary structure remains nearly the same with a small decrease in α-helix content and 
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small increase in random coil content. However, at longer times (125 and 120 min) a 
sharp decrease of α-helices and a sharp increase of β-sheets take place in both insulins. It 
is also noticeable that after 120 minutes bovine insulin has more β-sheet content than 
human insulin (75.0 vs. 60.3%). 
 
 
Table 3.6. Secondary structure percentage of human and bovine insulin in the 
presence of liposome 2 (20/80 PC/C) incubated at 60 ˚C. 
  
























35.1 2.9 50.7 7.5 3.7 0 
0.0 2.3 55.3 35.8 6.6 35 
0.0 4.3 85.1 5.2 5.4 65 
23.3 5.5 19.9 29.8 21.5 95 
10.9 1.6 13.0 14.2 60.3 125 








33.1 5.1 47.1 9.0 5.6 0 
41.7 3.7 42.9 6.2 5.6 60 
0.0 2.3 0.8 21.9 75.0 120 
2.3 6.2 0.4 20.1 71.0 180 




Table 3.7. Secondary structure percentage of human and bovine insulin in the 
presence of liposome 3 (80/20 PC/C) incubated at 60 ˚C. 
 
  























32.7 4.4 39.0 17.8 6.0 0 
0.0 5.1 86.0 5.4 3.5 35 
0.0 5.3 85.3 5.2 4.2 65 
6.7 4.2 42.5 7.9 38.7 95 
12.4 0.8 13.5 13.3 60.1 125 








35.5 7.4 43.6 7.0 6.5 0 
36.2 5.1 44.8 6.6 7.3 60 
3.0 3.9 0.4 19.6 73.1 120 
2.4 5.4 0.6 20.4 71.2 180 
1.4 3.2 2.4 19.9 73.2 240 
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 The secondary structures of both insulins incubated at 60 ˚C (sources 2 and 6) in 
the presence of liposome 3 (80/20 PC/C) before heating (time 0) are very similar (Table 
3.7) with the exception of β-turn content: 17.8 % (human insulin) and 7.0 % (bovine 
insulin). As time increases (65 and 60 min), a considerable increase in α-helices (85.3%) 
and the loss of random coils occur in human insulin but the secondary structure of bovine 
insulin remains relatively the same. Nonetheless, at longer times (125 and 120 min), a 
sharp decrease of α-helices and a sharp increase of β-sheets occurs in both insulins. It is 
also noticeable that after 120 minutes bovine insulin has more β-sheets than human 
insulin (73.1 vs. 60.1%). 
 
Table 3.8. Secondary structure percentage of human and bovine insulin in the 
presence of liposome 6 (50/50 PC/C) incubated at 60 ˚C. 
  
























19.4 5.3 24.0 36.3 15.1 0 
0.0 6.8 67.8 10.3 15.1 35 
0.0 4.0 38.9 36.6 20.4 65 
6.5 5.9 51.4 3.3 33.0 95 
12.0 1.6 10.9 15.7 59.7 125 








34.2 6.1 49.9 6.1 3.7 0 
4.3 5.7 0.7 21.1 68.2 60 
1.8 5.7 2.1 21.6 68.8 120 
5.1 6.3 0.9 23.0 64.8 180 




 The secondary structure of both insulins incubated at 60 ˚C (sources 2 and 6) in 
the presence of liposome 6 (50/50 PC/C) before heating (time 0) is very different. Human 
insulin contains a lot less random coils (19.4%) and α-helices (24.0%) than bovine insulin 
(34.2% and 49.9%, respectively). On the other hand, the β-turn and β-sheet contents are 
much higher in human insulin (36.3% and 15.1%, respectively) than in bovine insulin 
(6.1% and 3.7%, respectively) (Table 3.8). As time elapses (65 and 60 min), an increase 
in α-helices (38.9%) and β-sheets (20.4%) and the loss of random coils occur in human 
insulin; in bovine insulin, the amount of random coils (4.3%) and α-helices (49.9%) 
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decreases  but β-turns and β-sheets increase (21.1% and 68.2%, respectively). At longer 
times (125 and 120 min), a decrease in α-helices and an increase in β-sheets are observed 
for both insulins. It is evident that after 120 minutes bovine insulin has higher β-sheet 
content than human insulin (68.8 vs. 59.7%). 
 The secondary structure of both insulins incubated at 60 ˚C (sources 2 and 6) in 
the presence of PS-NH2 before heating (time 0) is different (Table 3.9); β-turn and β-
sheet contents are higher in human insulin (22.9% and 11.5%, respectively) than in 
bovine insulin (7.1% and 7.9%, respectively) but the amounts of random coils and α-
helices are lower in human insulin (23.6% and 39.1%, respectively) than bovine insulin 
(36.3% and 48.3%, respectively). At longer times (65 and 60 min), a considerable 
increase in α-helices (69.8%), the loss of random coils and a decrease in β-sheets (3.3%) 
occur in human insulin; the amount of random coils is also reduced in bovine insulin 
(3.0%) but a reduction of α-helices (0.8%) and an increase in β-turns (23.1%) and β-
sheets (71.2%) take place. At longer times (125 and 120 min), a sharp decrease of α-
helices (12.4%) and a sharp increase of β-sheets (57.7%) occur in human insulin; 
conversely, the secondary structure of bovine insulin remains constant. It is clear that 





Table 3.9. Secondary structure percentage of human and bovine insulin in the 
presence of PS-NH2 incubated at 60 ˚C. 
  
























23.6 2.9 39.1 22.9 11.5 0 
0.0 1.3 84.0 7.5 7.2 35 
0.0 0.3 69.8 26.6 3.3 65 
0.0 1.2 87.3 8.5 3.0 95 
8.3 8.8 12.4 12.7 57.7 125 








36.3 0.4 48.3 7.1 7.9 0 
3.0 1.8 0.8 23.1 71.2 60 
3.0 4.8 0.3 21.6 70.3 120 
4.1 4.2 0.7 22.4 68.6 180 
0.3 3.0 1.4 22.9 72.4 240 
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The secondary structure of both insulins incubated at 60 ˚C (sources 2 and 6) in the 
presence of PS-COOH before heating (time 0) is different to some extent. Human insulin 
contains a lot less α-helices (21.0%) than bovine insulin (54.5); on the other hand, human 
insulin contains more β-turns (37.6%) and β-sheets (14.2%) than bovine insulin (6.3% 
and 6.7%, respectively); the amounts of random coils and side chains are similar in both 
insulins (Table 3.10). As time increases (65 and 60 min), a sharp increase in α-helices 
(87.6%) and the loss of random coils occur in human insulin whereas there is a decrease 
in random coils (9.5%) and α-helices (36.6%) but an increase in β-sheets (45.8%) in 
bovine insulin. At longer times (125 and 120 min), an abrupt decrease in α-helices and an 
increase in β-sheets take place in both insulins. After 120 minutes bovine insulin has 
more β-sheets than human insulin (69.3% vs. 60.1%). 
 
 
Table 3.10. Secondary structure percentage of human and bovine insulin in the 
presence of PS-COOH incubated at 60 ˚C. 
  
























21.3 5.9 21.0 37.6 14.2 0 
0.0 1.3 85.4 6.9 6.3 35 
0.0 3.2 87.6 6.6 2.5 65 
0.0 2.8 84.1 6.1 7.0 95 
3.2 15.0 0.0 21.7 60.1 125 








29.8 2.6 54.5 6.3 6.7 0 
9.5 4.0 36.6 4.1 45.8 60 
1.2 5.7 2.9 20.9 69.3 120 
0.7 6.3 0.9 22.4 69.6 180 




 The secondary structure of both insulins incubated at 37 ˚C and 230 rpm (sources 
1 and 6) in the presence of liposome 2 (20/80 PC/C) before heating (time 0) is relatively 
similar (Table 3.11. At longer times (17 hr), a decrease of random coils and α-helices 
occurs in both insulins. The amount of β-turns slightly decreases in human insulin (9.9%) 
but slightly increases in bovine insulin (18.5%). The amount of β-sheets increases in 
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human insulin (36.5%) and in bovine insulin (73.8%). At longer times (45 hr), a sharp 
decrease of α-helices (8.2%) and a sharp increase of β-sheets (69.7%) occur in human 
insulin while the secondary structure of bovine insulin remains the same. At this point 
both insulins have a similar amount of β-sheets but human insulin has more α-helices but 
less β-turns than bovine insulin. 
 
 
Table 3.11. Secondary structure percentage of human and bovine insulin in the 
presence of liposome 2 (20/80 PC/C) incubated at 37 ˚C and 230 rpm. 
  























 30.5 2.2 55.2 12.2 0.0 0 
12.7 0.2 40.7 9.9 36.5 17 
6.0 1.2 8.7 19.4 64.8 25 
4.0 0.0 8.6 17.6 69.8 36 








32.8 7.0 49.3 7.9 3.1 0 
2.8 5.5 5.2 20.1 66.3 10 
2.0 2.8 2.8 18.5 73.8 17 
2.7 3.7 4.8 20.7 68.2 24 
2.4 5.3 3.8 20.3 68.2 36 
3.1 2.8 2.3 22.3 69.5 45 
 
 
Table 3.12. Secondary structure percentage of human and bovine insulin in the 
presence of liposome 3 (80/20 PC/C) incubated at 37 ˚C and 230 rpm. 
  
























28.4 1.4 57.7 12.4 0.0 0 
15.1 2.0 15.4 25.2 42.3 17 
4.7 0.0 8.7 18.0 68.6 25 
4.0 0.0 5.7 19.7 70.6 36 








33.7 6.7 48.3 6.9 4.3 0 
19.5 5.2 20.1 15.6 39.5 10 
1.8 7.4 28.7 14.3 47.8 17 
7.1 4.8 9.3 22.5 56.2 24 
3.6 4.1 4.6 19.4 68.3 36 
0.0 3.0 3.7 22.0 71.2 45 
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 Table 3.12 summarizes the secondary structure results obtained for both insulins 
incubated at 37 ˚C and 230 rpm (sources 1 and 6) in the presence of liposome 3 (80/20 
PC/C). Before heating (time 0), the secondary structure of both preparations is similar. At 
longer times (17 hr), a decrease in the amounts of random coils and α-helices occur in 
human, 15.1% (random coil) and 15.4% (helix), and bovine, 1.8% (random coil) and 
28.7% (helix), insulins. The amount of β-turns and β-sheets increases in human, 25.2% 
(turns) and 42.3% (sheets), and bovine, 14.3% (turns) and 47.8% (sheets), insulins. At 
even longer times (45 hr), a further decrease in α-helices takes place: 8.7% (human 
insulin) and 3.7% (bovine insulin) and a sharp increase of β-sheets occurs: 69.8% (human 
insulin) and 71.2% (bovine insulin). Both insulins have similar β-sheet contents at the 





Table 3.13. Secondary structure percentage of human and bovine insulin in the 
presence of liposome 5 (10:5:7.5:16 PC/PE/PS/C) incubated at 37 ˚C and 230 rpm. 
  























 0.0 10.4 33.9 2.3 53.4 0 
13.8 1.2 45.3 6.9 32.8 17 
13.5 2.0 14.5 23.5 46.5 25 
4.7 0.0 9.4 16.8 69.1 36 








34.2 3.3 49.9 10.2 2.5 0 
0.0 4.3 6.5 20.1 69.2 10 
0.9 4.4 7.7 17.4 69.5 17 
0.0 2.8 4.8 22.5 69.8 24 
3.0 2.5 6.0 18.7 69.8 36 




 The secondary structures of both insulins incubated at 37 ˚C and 230 rpm (sources 
1 and 6) in the presence of liposome 5 (10:5:7.5:16 PC/PE/PS/C) before heating (time 0) 
are very different (Table 3.13). The side chain and β-sheet contents are higher in human 
(10.4% and 53.4%, respectively) than in bovine insulin (3.3% and 2.5%, respectively) but 
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the amounts of random coils, α-helices and β-turns are lower in human (0%, 33.9% and 
2.3%, respectively) than in bovine insulin (34.2%, 49.9% and 10.2%, respectively). At 
longer times (17 hr), reductions in the percentage of side chains (1.2%) and β-sheets 
(32.8%) and increases in random coils (13.8%), α-helices (45.3%) and β-turns (6.9%) 
take place in human insulin. For bovine insulin, reductions in the percentage of random 
coils (0.9%) and α-helices (7.7%) and an increase in β-turns (17.4%) and β-sheets 
(69.5%) occur. At even longer times (45 hr), a sharp decrease of α-helices (9.0%) and a 
sharp increase of β-sheets (63.5%) occur in human insulin whereas the secondary 
structure contents of bovine insulin remain almost unchanged; α-helix: 3.9%, β-turn: 




Table 3.14. Secondary structure percentage of human and bovine insulin in the 
presence of PS-NH2 incubated at 37 ˚C and 230 rpm. 
  























 32.4 1.4 54.3 11.9 0.0 0 
11.3 0.6 29.5 17.6 41.0 17 
1.3 0.0 8.7 17.3 72.7 25 
1.1 0.0 6.4 18.6 73.9 36 








27.0 2.2 54.4 13.7 2.7 0 
11.5 4.1 4.7 19.6 60.0 10 
4.1 2.7 3.8 20.4 69.0 17 
2.4 4.4 3.2 21.6 68.3 24 
4.4 5.4 4.3 19.8 66.2 36 




Table 3.14 shows the secondary structure content of both insulins incubated at 37 
˚C and 230 rpm (sources 1 and 6) in the presence of PS-NH2. Before heating (time 0), the 
distribution of secondary for both insulins is nearly the same. At longer times (17 hr), a 
decrease in the amount of random coils and α-helices and an increase of β-turns and β-
sheets are observed for both insulins. At even longer times (45 hr), a further decrease in 
α-helix takes place for both insulins and a sharp increase in the amount of β-sheets occurs 
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in human insulin (75.5%). At the end of the incubation period the distribution of 




Table 3.15. Secondary structure percentage of human and bovine insulin in the 
presence of PS-COOH incubated at 37 ˚C and 230 rpm. 
  























 37.1 2.4 53.6 6.9 0.0 0 
12.0 3.0 13.9 22.8 48.3 17 
2.1 0.0 11.7 14.6 71.7 25 
1.7 0.0 11.1 15.7 71.6 36 








25.9 3.3 53.0 14.5 3.3 0 
10.0 4.2 12.3 16.7 56.7 10 
2.3 2.7 19.6 10.0 65.4 17 
4.2 1.1 9.1 17.4 68.2 24 
6.2 3.3 7.8 17.9 64.9 36 




The distribution of secondary structures of both insulins incubated at 37 ˚C and 
230 rpm (sources 1 and 6) in the presence of PS-COOH before heating (time 0) is 
somewhat similar (Table 3.15). At longer times (17 hr), a decrease in random coil and α-
helix content takes place for human (12.0% and 13.9% for coil and helix respectively) 
and bovine (10.0% and 12.3% for coil and helix respectively) insulins. An increase in the 
amount of β-turns is observed in human insulin (22.8%) but a decrease is observed in 
bovine insulin (10.0%). The β-sheet content increases in both human (48.3%) and bovine 
(65.4% ) insulins. At longer times (45 hr), a further decrease in random coil (2.1%), α-
helix (9.9%) and β-turn (14.7%) but a sharp increase in β-sheet (73.3%) contents is 
observed in human insulin whereas the secondary structure of bovine insulin remains 
almost unchanged. 
Four transitions are evident for human insulin incubated at 60 
o
C (source 2) in 
bulk and in the presence of liposomes 2 (20/80 PC/C) and 3 (80/20 PC/C). The first 
transition (0-35 min) may correspond to the dissolution of the protein in which an 
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increase in α-helix and the total depletion of random coil structures take place. The 
second transition (35-65 min) may be attributed to the changes inside the dimeric insulin 
in the nucleation phase, along with a constant content of secondary structure (human 
insulin in bulk and in the presence of liposome 3) or a continuous increase of α-helix 
conformation ( human insulin in the presence of liposome 2). The third transition (65-95 
min) may correspond to the conversion of α-helices into random coils and β-sheets. After 
125 minutes, the conformation of the insulin solution is predominantly β-sheet. 
Only three transitions are observed for human insulin incubated at 60 ˚C (source 
2) in the presence of PS-COOH beads. The first transition (0-35 min) is similar to that of 
human insulin in bulk and in the presence of liposomes 2 and 3 in which a tremendous 
increase in α-helix content and the complete depletion of random coils occur. Between 35 
to 95 minutes (second transition) the secondary structure remains unchanged. However, 
after 95 minutes (third transition), an abrupt decrease in α-helix and a large increase in β-
turns and β-sheets take place, after this point the secondary structure remains somewhat 
constant with a small reduction of β-turns and sheets. 
Four transitions are observed when human insulin is incubated 60 ˚C (source 2) in 
the presence of liposome 6 (50/50 PC/C) or PS-NH2 beads. Once more, the first transition 
(0-35 min) is similar to that of human insulin in bulk and in the presence of all the 
surfaces in which an increase in α-helix and the complete depletion of random coils take 
place. The second transition (35-65 min) consists of the replacement of α-helices by 
(mainly) β-turns and β-sheets. The third transition (65-95 min) consists of an increase in 
α-helices and a decrease in (mainly) β-turns and β-sheets. The fourth transition (95-125 
min) consists of a replacement of α-helices by mostly β-sheets.  
The sampling frames used with bovine insulin (source 6) are different from those 
used with human insulin (source 2), at the same incubation conditions (60 
o
C). In the case 
of bovine insulin in bulk and in the presence of surfaces some secondary structure 
changes could have been missed  between 60-120 minutes. For bovine insulin in bulk, the 
first transition (0-60 min) is similar to that observed with human insulin in bulk and in the 
presence of surfaces; i.e. an increase in α-helices and the complete depletion of random 
coils. In the second transition (60-120 min), the complete conversion of α-helices into β-
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turns and (mostly) β-sheets takes place. After 120 minutes the secondary structure of 
bovine insulin in bulk remains unchanged with a high content of β-sheets.  
Only one transition is evident for bovine insulin incubated at 60˚C (source 6) in 
the presence of liposomes 2 (20/80 PC/C) or 3 (80/20 PC/C). For the most part, the 
secondary structure did not change much between 0-60 minutes; there was a slight 
increase in random coils and a small decrease in α-helices in the presence of liposome 2. 
Therefore, the first transition took place between 60-120 minutes in which a complete 
depletion (in the presence of liposome 2) or a significant reduction (in the presence of 
liposome 3) of random coils and a considerable reduction of α-helices occurs. The 
predominant structures at the end of the incubation were β-sheets and to a lesser extent β-
turn.  
Similarly, only one transition is observed for bovine insulin incubated at 60 
o
C 
(source 6) in the presence of liposome 6 (50/50 PC/C) or PS-NH2 beads. The transition 
takes place within the first hour (0-60 min) in which the random coil and α-helix 
conformations are significantly reduced and replaced by mainly β-sheets. After 60 
minutes, no more conformational changes are observed.  
When incubated at 37 ˚C and 230 rpm, human insulin (source 1) in bulk shows 
two transitions. Its secondary structure remains virtually unchanged for the first 17 hours; 
hence, the initial transition takes place between 17-25 hours. During this time the 
dissolution of the protein may occur and a large increase in α-helix and the complete 
depletion of random coil conformations take place. After 36 hours, the secondary 
structure remains constant. Throughout the second transition (36-45 hr) a significant 
decrease in α-helix and an increase of  side chains, β-turns and (mainly) β-sheet takes 
place. 
Human insulin incubated at 37 ˚C and 230 rpm (source 1) in the presence of 
liposome 2 (20/80 PC/C), liposome 3 (80/20 PC/C), PS-NH2 or PS-COOH goes through 
the same changes in secondary structure. During the first transition (0-17 hr) a reduction 
of random coils and α-helices and an increase of β-sheets takes place. A second transition 
takes place after 17 hours in which a further reduction in random coils and α-helices and 
a further increase of β-turns and β-sheets occur. 
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Human insulin incubated at 37 ˚C and 230 rpm (source 1) in the presence of 
liposome 5 (10:5:7.5:16 PC/PE/PS/C) shows three transitions in secondary structure. The 
first transition (0-17 hr) may correspond to the dissolution of the protein; interestingly, 
the β-sheet content at time 0 is really high (53.4%), during this time a depletion of β-
sheet into random coil and α-helix structures takes place. The second transition (17-25 hr) 
consists of a reduction in α-helices and an increase in β-turns and β-sheets. After 25 hours 
(third transition), β-sheets are the predominantly structures. 
When incubated at 37 ˚C and 230 rpm, bovine insulin (source 6) in bulk and in 
the presence of liposome 3 (80/20 PC/C) shows two transitions. During the initial 
transition (0-10 hr) a complete depletion of random coils, a reduction of α-helices, and an 
increase in the amounts β-sheets, and to a lesser extent turns, take place. The secondary 
structure remains somewhat stable between 10-17 hours. After 17 hours, the second 
transition takes place in which a further replacement of α-helices by β-turns takes place.  
Only one transition is observed for bovine insulin incubated at 37 ˚C and 230 rpm 
(source 6) in the presence of liposomes 2 (20/80 PC/C), liposome 5 (10:5:7.5:16 
PC/PE/PS/C), or PS-NH2 beads. The transition takes place between 0-10 hours in which 
the amount of random coils and α-helices is significantly reduced with the simultaneous 
increase of β-sheets and turns. After 10 hours, no more conformational changes are 
observed.  
Three transitions are observed for bovine insulin incubated at 37 ˚C and 230 rpm 
(source 6) in the presence of PS-COOH beads. Replacement of α-helices and random 
coils by β-sheet takes place during the first transition (0-10 hr). Between 10 and 17 hours 
(second transition) a replacement of β-turns and β-sheets by α-helices occurs. A decrease 
in α-helices and an increase in β-turns and β-sheets takes place after 17 hours (third 
transition); after this point the secondary structure remains fairly constant.  
Bovine insulin amyloid fibril formation in bulk (incubated at 68 ˚C at pD 2.6, i.e. 
pH 2.2, at a concentration of 2.0 mM) was studied by Bouchard et al. (2000). Their 
sample preparation included leaving the protein at pD 1.9 at room temperature for 12 
hours followed by lyophilization (this procedure was repeated until the labile hydrogen in 
the sample were completely replaced by deuterium). Their results show that before 




, respectively. Heating the sample for 1.5 hours results in a slight increase 
in the content of random coil structure, although the protein remains mostly helical. 
Similar to us, they also observed a shift of the IR band at about 1651 cm
-1
 with increasing 
incubation time toward lower frequencies and the appearance of a small shoulder on this 
band. After 18 hours of heating, the predominant secondary structure was β-sheet. 
Secondary structure percentages were not reported. 
Nielsen et al. (2000) used bovine insulin in bulk (at a concentration of 20 mg/mL 
in 0.05 M HCl, pH 1.6 incubated at 50 °C for 7 hours or agitated at 37 °C for 24 hours) to 
investigate fibril formation of insulin in acid media. Their FTIR spectroscopy studies 
showed that the native secondary structure of insulin was identical in hydrochloric acid 
and acetic acid, whereas the secondary structure of fibrils formed in hydrochloric acid 
was different from that formed in acetic acid. Fibrils of bovine insulin prepared by 
heating or agitating an acid solution of insulin showed an increased content of β-sheet 
and a decrease in the intensity of the α-helix band. In hydrochloric acid, the frequencies 
of the β-sheet bands depended on whether the fibrillation was induced by heating or 
agitation.  
Liu et al. (2010) investigated the fibrillation of bovine insulin in bulk at a 
concentration of 2 mg/ml in 20% acetic acid incubated at 60 ˚C. They also obtained 
sigmoidal curves from their ThT fluorescence kinetic experiments which reached the 
equilibrium phase after 70 hours of incubation. Furthermore, they noticed four different 
structural transitions occurring during the process of insulin fibrillation. Namely, the 
initial transition, characterized by the dissolution of insulin and an increase in α-helices; 
the second transition, which may be attributed to changes in the insulin monomer during 
the nucleation phase; the third transition, in which a replacement of α-helices by β-sheets 
is evident and the final transition in which most of insulin solution was in a β-sheet 




3.3. DYNAMIC LIGHT SCATTERING 
An effort to follow insulin aggregation by dynamic light scattering (DLS) was 
made. The results are sensitive to bubbles and dust and therefore, some of them are 
inconclusive.  
The autocorrelation functions were analyzed by means of the program CONTIN. 
Size distribution histograms were generated in which relative scattering intensities and 
relative scattering by number were plotted versus particle diameter. The aggregation of 
insulin in bulk and in the presence of surfaces incubated at 37 ˚C and 230 rpm for up to 
55 hours was particularly challenging to follow.  
Figure 3.12 shows two typical histograms. The left panel corresponds to intensity 
averages where the presence of dust is evident (the scattering is dominated by the largest 
particles).  The right panel corresponds to number averages where the “dust signal” has 
disappeared and the size corresponds roughly to insulin monomer/dimer.  
 
 
Figure 3.12. DLS analysis of bovine insulin (source 4) aggregation in bulk. 
Histograms represent relative scattering by intensity (a) and by number (b). Results 
shown are for: (1a) & (1b) before incubation.  The signal at a few micrometers is 
due to dust.  
 
 
The quality of most experimental runs was quite poor. We used a couple of 
simple tools to clean the data. First, data sets with differences between calculated and 
experimental base lines higher than 1% were eliminated. Second, all data sets poorly 
fitted by the CONTIN algorithm were excluded. Unfortunately, many sample sets lost 
































Appendices B, C and D for completeness but they have not been thoroughly analyzed. 
None of the data taken at 37 
o
C survived.  
 
 
3.4. CONGO RED HISTOLOGICAL DYE BINDING TO INSULIN FIBRILS  
 Congo red strongly stains amyloid aggregates by binding to the β-pleated sheet 
conformation of the protein (Klunk et al., 1989). This technique was used to confirm the 
presence of amyloid deposits at the end of each experiment. A representative absorbance 
spectrum of Congo red solution in the presence of β-pleated bovine insulin is shown in 
Figure 3.13. The remaining spectra are included in Appendix E.  
 
Figure 3.13.  Congo red spectrum of bovine insulin incubated at 37 ˚C and 230 rpm 




3.5. TRANSMISSION  AND SCANNING ELECTRON MICROSCOPY  
All the micrographs were obtained from the same sample unless otherwise 
specified. All samples were prepared in 0.025 M HCl and 0.1 M NaCl (pH 1.6). 
Statistical analysis of the size distribution of the length of the fibrils was performed, 
when possible. It is well known that amyloid fibrils have a width of 10-20 nm (Knowles 
























fibrils was conducted as well in order to fully characterize the amyloid fibrils and make a 
sound comparison of the obtained results to those from the literature. Negative stained 
micrographs of different samples under different incubation conditions in the presence 
and in the absence of surfaces were acquired for both bovine and human insulin.  
Figure 3.14 shows micrographs of human and bovine insulin incubated at 60 ˚C 




Figure 3.14. Negative staining transmission electron images of amyloid fibril 
formation of (a) human and (b) bovine insulin incubated at 60 ˚C for 6 hours.  The 




The data is summarized in Table 3.16 and Figure 3.15. The mean length of human 
insulin fibrils is 158±24 nm while that of bovine insulin is 155±33 nm, with the longest 
insulin fibril being 173 nm and that of bovine insulin 213 nm.   The average width of the 
fibrils was measured to be 12±2 nm and 13±1 nm for human and bovine insulin, 





Table 3.16. Statistical analysis of the length of human and bovine insulin incubated 












(a) 158 24 102 169 173 




Figure 3.15. Length distribution of (A) human and (B) bovine insulin incubated at 
60˚C for six hours. 
 
 
Table 3.17. Statistical analysis of the width of human and bovine insulin incubated 












(a) 12 2 10 12 15 






Figure 3.16. Width distribution of (A) human and (B) bovine insulin incubated at 




In agreement with Liu et al., 2010, it was observed that fibrils attain a larger size 
when incubated for longer periods of time and under no mechanical stresses (i.e. stirring). 
These differences were observed between insulin incubated at 60˚C for 6 (Figure 3.14) 
and 40 (Figure 3.17) hours. Figures 3.17, 3.25, and 3.27 confirm these results. Liu et al. 





Figure 3.17. Negative staining transmission electron images of amyloid fibril 
formation of human and bovine insulin incubated at 60 ˚C for 40 hours. (a) and (b) 




A statistical analysis of the length distribution of a few fibrils (most fibrils extend 
further outside the image) from Figure 3.17 was performed. The results are shown in 
Table 3.18. The mean length of human insulin fibrils is 1197±148 nm while that of 
bovine insulin is 1092±168 nm. These results clearly demonstrate the increase in length 
with increasing incubation time (without mechanical stresses). Figure 3.18 shows the 







Table 3.18. Statistical analysis of the length of human and bovine insulin incubated 












(a) & (b) 1197 148 1046 1186 1432 






Figure 3.18. Length distribution of (A) human and (B) bovine insulin incubated at 




The average width of the fibrils was measured to be 18±2 nm and 15±3 nm for 





Table 3.19. Statistical analysis of the width of human and bovine insulin incubated 












(a) & (b) 18 2 15 19 20 






Figure 3.19. Width distribution of (A) human and (B) bovine insulin incubated at 




Figure 3.20 shows that human insulin fibrils formed by incubation at 37 ˚C with 
stirring at 230 rpm for 55 hours look as if they had been “fragmented”. Their size was 




(1983) showed that fibril fragmentation is a mechanism that drastically minimizes fibril 





Figure 3.20. Negative staining transmission electron images of amyloid fibril 
formation of human insulin incubated for 55 hours at 37 ˚C and 230 rpm.  The scale 




When insulin is incubated at 37 ˚C with stirring at 230 rpm for 55 hours the 
median fibril length is 71±64 nm, with the smallest fibril length being 25 nm and the 




shown in the bimodal histogram in Figure 3.21 (A), were found between 200 to 400 nm. 
Therefore, a second analysis of the densest population (i.e. without taking into account 
fibrils larger than 300 nm) was performed (Figure 3.21 (B)) to obtain a more precise 
distribution of the length of the fibrils. The median fibril length became 68±44 nm. 
(Table 3.20 (B)). Overall, under these conditions, most of the fibrils do not reach an 




Table 3.20. Statistical analysis of the length of human insulin incubated at 37˚C and 












(A): (a) to (d) 88 64 25 71 362 
(B): (a) to (d) 80 44 25 68 208 
 
 
Table 3.21 shows that the average width of the human insulin fibrils is 14±3 nm. 
Figure 3.22 depicts the histogram of such results. The same “fragmentation” occurred to 
bovine insulin under the same incubation conditions (37 ˚C and 230 rpm) (Figure 3.23). 
 
 
Table 3.21. Statistical analysis of the width of human insulin incubated at 37˚C and 






















Figure 3.21. Length distribution of human insulin incubated at 37˚C and 230 rpm 




Table 3.22. Statistical analysis of the length (A) and width (B) of bovine insulin 












(A): (a) to (d) 128 68 45 107 327 








Figure 3.22. Width distribution of human insulin incubated at 37˚C and 230 rpm for 
55 hours. 
 
Comparing the length distributions of both insulins one may conclude that while 
bovine insulin fibrils were also fragmented, they are longer and thinner than human 
insulin fibrils. When human insulin is incubated at 37 ˚C with stirring at 230 rpm for 55 
hours the median fibril length is 71±64 nm, with the smallest fibril length being 25 nm 
and the longest fibril attaining a size of 362 nm (Table 3.20 (A)). In contrast, the mean 
fibril length of bovine insulin is 128±68 nm with the shortest fibril being 45 nm and the 
longest fibril 327 nm (a few longer fibrils were present but they were curved, therefore, 
they were not measured) (Table 3.22, Figure 3.24). The average width of the human 
insulin fibrils is 14±3 nm (Table 3.21) whereas the average width of bovine insulin fibrils 
is 11±1 nm, under the same conditions. 
Figure 3.25 shows images of amyloid fibril formation of human and bovine 
insulin in the presence of liposome 3 (80/20 PC/C) incubated at 60 ˚C for 40 hours. 
Regardless of the presence or the absence of surfaces, human and bovine insulin showed 







Figure 3.23. Negative staining transmission electron images of amyloid fibril 
formation of bovine insulin incubated for 55 hours at 37 ˚C and 230 rpm.  The scale 




A statistical analysis of the length distribution of the fibrils from Figure 3.25 was 
not possible due to the fact that most fibrils extend further outside the image. However, 
the fibrils have similar morphologies and nearly all fibrils are several microns in length. 
The average width of the fibrils was measured to be 15±3 nm and 15±3 nm for human 







Figure 3.24. Length (A) and width (B) distributions of bovine insulin incubated and 









Figure 3.25. Negative staining transmission electron images of amyloid fibril 
formation of human and bovine insulin in the presence of liposome 3 (80/20 PC/C) 
incubated at 60 ˚C for 40 hours. (a) and (b) Human insulin. (c) and (d) Bovine 




Table 3.23. Statistical analysis of the width of human and bovine insulin in the 












(a) & (b) 15 3 10 15 20 






Figure 3.26. Width distribution of (A) human and (B) bovine insulin in the presence 
of liposome 3 (80/20 PC/C) incubated at 60 ˚C for 40 hours. 
   
 
Figure 3.27 shows that in the presence of PS-COOH surfaces longer fibrils were 
also obtained when incubated for longer periods of time, without stirring. These 










Figure 3.27. Negative staining transmission electron images of amyloid fibril 
formation of human insulin in the presence of PS-COOH. Images were obtained 
from two different samples: (a) and (b) were obtained from one sample while (c) and 
(d) were obtained from another sample. (a) and (b) incubated for 6 hours. (c) and 
(d) incubated for 40 hours. The scale bar represents 100 nm (a) and (b) and 500 nm 
(c) and (d).  
 
When insulin (in the presence of PS-COOH) is incubated for six and 40 hours at 
60 ˚C the fibrils attain an average length of 96±43 nm, and 1278±511 nm, respectively 




six and 40 hours at 60 ˚C the fibrils attain an average width of 13±2 nm and 15±4 nm, 
respectively (Table 3.25 and Figure 3.29).  
Table 3.24. Statistical analysis of the length of human insulin in the presence of PS-












(A): (a) & (b)  96 43 35 90 201 




Figure 3.28. Length distribution of human insulin in the presence of PS-COOH 




Table 3.25. Statistical analysis of the width of human insulin in the presence of PS-












(A): (a) & (b) 13 2 10 12 18 





Figure 3.29. Width distribution of human insulin in the presence of PS-COOH 










Not all the surfaces shorten the lag time (this is more evident for both insulins 
incubated at 60 ˚C). On the other hand, most surfaces had an impact (either significant or 
minute) on the growth rate of both insulins. The downhill mechanism can be used to 
describe the results represented by a sigmoidal curve while the “seeded” results can be 
described by the classical-nucleation polymerization model. An autocatalytic reaction 
may be plausible as well in which the formed fibril in solution can act as a preferential 
site for new nucleation or elongation events. Furthermore, several mechanisms may be 
necessary to fully describe the complex insulin aggregation process. In addition, it is 
probable that one mechanism is dominant at certain experimental conditions or at a 
certain stage in the aggregation process while another is more dominant at another stage.  
Structural changes taking place during fibril formation were followed. In general, 
the initial transition in which the the insulin decreases from random coil into α-helix 
conformation may be attributed to the dissolution of the insulin. The second transition 
along with a constant or a continuous increase in α-helix structure could be due to the 
changes within the dimeric protein in the nucleation phase; throughout this transition, the 
reaction pathway may be chosen and the formation of the active centers may take place. 
However, which one occurs first? Is it the reaction the one that dictates the type of 
nucleus/active centers or is the nucleus/active centers the one that dictates the reaction 
pathway? We don’t know but we do know that the choice of experimental conditions 
(temperature, mechanical stresses, pH, concentration, etc.) are a determinant factor in the 
rate of insulin aggregation and the amyloid fibril morphologies; this can give further 
insights into the reaction mechanism(s) and the subsequent build up of a model.  
Since our results show different reactions (this is clear from the turbidimetry 
graphs) we have more than one mechanism present). The third transition in which a 
reduction in α-helix and an increase in β-turn and β-sheet take place may be attributed to 
the precipitation phase in which floccule formation could take place. The final transition 
in which the secondary structure of the insulin is predominantly β-sheet may depict, 
63 
depending on the incubation conditions, the elongation phase of the mature insulin fibrils 
or the formation of spherulites.  
Both, human and bovine insulin formed fibril of similar morphologies (i.e. similar 
length, width, and structure) when treated under the same conditions in the presence and 
in the absence of surfaces with the exception of incubation at 37 ˚C and 230 rpm stirring 
for 55 hours. In addition, when human and bovine insulin are subjected to mechanical 
stresses the fibrils appear “fragmented” and hence their size is smaller when compared to 
insulin that has not been agitated. Bovine insulin fibrils were longer and thinner under 
these incubation conditions (37 ˚C and 230 rpm) than human insulin fibrils. Incubation 
temperatures were different between agitated insulin (37 ˚C) and non-agitated insulin (60 
˚C).  It is also noticeable that at 60 ˚C larger fibrils formed at longer incubation times. 
The width of the fibrils ranged between 10 to 20 nm, there is not a noticeable 
dependence/correlation between fibril length and width for human or bovine insulin. On 
the other hand, based on the obtained images, the statistical analysis, and in agreement 
with literature the incubation methods utilized determined the fibril morphologies.  
Nielsen et al. (2000b) have concluded that the fibrillation of bovine insulin has 















INSULIN FIBRILS BY THE METHOD OF BURKE AND ROUGVIE 
65 
Usually, a 1 % solution of insulin in water is adjusted to pH 2.0 with hydrochloric 
acid and the solution is placed in a sealed-glass test tube. The tube is heated in a water 
bath to between 80 and 100 °C until a clear gel is formed. The time required for gelling is 
between 2 and 10 minutes depending on the exact temperature and pH. The sample is 
then cooled and frozen rapidly by immersion in a dry ice acetone bath, thawed under 
running tap water, and reheated (80-100°) for approximately 2 min. The procedure of 
freezing and reheating is repeated three or four times until a firm gel is formed. Total 
conversion of native to fibrillar insulin is possible by this process. 
APPENDIX B 
 
DYNAMIC LIGHT SCATTERING HISTOGRAMS 
 
OF BOVINE INSULIN IN BULK AND IN THE PRESENCE OF POLYSTYRENE 
 






Figure B.1. DLS analysis of the blanks: histograms represent relative scattering by 
intensity (a) and by number (b). Results shown are for: (1a) & (1b) buffer solution after 7 




































































































































































































































































Figure B.2. DLS analysis of the blanks: histograms represent relative scattering by 
intensity (a) and by number (b). Results shown are for: (4a) & (4b) buffer+PSCOOH 
solution after 60 min; (5a) & (5b) buffer+PSNH2 before incubation; and (6a) & (6b) 

























































































































































































































Figure B.3. DLS analysis of bovine insulin (SIGMA, Cat. #: I5500 (lot 019K17765V) 
aggregation in bulk: histograms represent relative scattering by intensity (a) and by 
number (b). Results shown are for: (1a) & (1b) before incubation; (2a), (2b), (3a) & (3b) 




















































































Figure B.4. DLS analysis of bovine insulin (SIGMA, Cat. #: I5500 (lot 019K17765V) 
aggregation in bulk: histograms represent relative scattering by intensity (a) and by 
number (b). Results shown are for: (4a) & (4b) after 45 minutes; (5a), (5b), (6a) & (6b) 








































































































Figure B.5. DLS analysis of bovine insulin (SIGMA, Cat. #: I5500 (lot 019K17765V) 
aggregation in bulk: histograms represent relative scattering by intensity (a) and by 
number (b). Results shown are for: (7a), (7b), (8a) & (8b) after 120 minutes; and (9a) & 



















































































































































































































Figure B.6. DLS analysis of bovine insulin (SIGMA, Cat. #: I5500 (lot 019K17765V) 
aggregation in bulk: histograms represent relative scattering by intensity (a) and by 
number (b). Results shown are for: (10a) & (10b) after 180 minutes of incubation; and 






























































































































































Figure B.7. DLS analysis of bovine insulin (SIGMA, Cat. #: I5500 (lot 019K17765V) 
aggregation in the presence of PS surface: histograms represent relative scattering by 
intensity (a) and by number (b). Results shown are for: (1a), (1b), (2a), (2b), (3a) & (3b) 
















































































































































Figure B.8. DLS analysis of bovine insulin (SIGMA, Cat. #: I5500 (lot 019K17765V) 
aggregation in the presence of PS surface: histograms represent relative scattering by 
intensity (a) and by number (b). Results shown are for: (4a) & (4b) before incubation; 
(5a), (5b), (6a) & (6b) after 25 minutes of incubation. Sample (4) is the duplicate of 


























































































































































































































































Figure B.9. DLS analysis of bovine insulin (SIGMA, Cat. #: I5500 (lot 019K17765V) 
aggregation in the presence of PS surface: histograms represent relative scattering by 
intensity (a) and by number (b). Results shown are for: (7a), (7b), (8a) & (8b) after 30 

































































































































































































Figure B.10. DLS analysis of bovine insulin (SIGMA, Cat. #: I5500 (lot 019K17765V) 
aggregation in the presence of PS surface: histograms represent relative scattering by 
intensity (a) and by number (b). Results shown are for: (10a), (10b), (11a) & (11b) after 
60 minutes; and (12a) & (12b) after 90 minutes of incubation. Sample (11) is the 


















































































































































































Figure B.11. DLS analysis of bovine insulin (SIGMA, Cat. #: I5500 (lot 019K17765V) 
aggregation in the presence of PS surface: histograms represent relative scattering by 
intensity (a) and by number (b). Results shown are for: (13a) & (13b) after 120 minutes; 



























































































































































































































Figure B.12. DLS analysis of bovine insulin (SIGMA, Cat. #: I5500 (lot 019K17765V) 
aggregation in the presence of PS surface: histograms represent relative scattering by 
intensity (a) and by number (b). Results shown are for: (16a) & (16b) after 300 minutes; 












































































































































































Figure B.13. DLS analysis of bovine insulin (SIGMA, Cat. #: I5500 (lot 019K17765V) 
aggregation in the presence of PS surface: histograms represent relative scattering by 

















































































Figure B.14. DLS analysis of bovine insulin (SIGMA, Cat. #: I5500 (lot 019K17765V) 
aggregation in the presence of PS-OH surface: histograms represent relative scattering by 
intensity (a) and by number (b). Results shown are for: (1a), (1b), (2a), (2b), (3a) & (3b) 










































































































































Figure B.15. DLS analysis of bovine insulin (SIGMA, Cat. #: I5500 (lot 019K17765V) 
aggregation in the presence of PS-OH surface: histograms represent relative scattering by 
intensity (a) and by number (b). Results shown are for: (4a), (4b), (5a) & (5b) after 25 



















































































































































































































Figure B.16. DLS analysis of bovine insulin (SIGMA, Cat. #: I5500 (lot 019K17765V) 
aggregation in the presence of PS-OH surface: histograms represent relative scattering by 
intensity (a) and by number (b). Results shown are for: (7a) & (7b) after 30 minutes; (8a), 
(8b), (9a) & (9b) after 60 minutes of incubation. Sample (7) is the duplicate of sample (6) 






































































































































































































































Figure B.17. DLS analysis of bovine insulin (SIGMA, Cat. #: I5500 (lot 019K17765V) 
aggregation in the presence of PS-OH surface: histograms represent relative scattering by 
intensity (a) and by number (b). Results shown are for: (10a), (10b), (11a) & (11b) after 
65 minutes; and (12a) & (12b) after 85 minutes of incubation. Sample (11) is the 








































































































































































































Figure B.18. DLS analysis of bovine insulin (SIGMA, Cat. #: I5500 (lot 019K17765V) 
aggregation in the presence of PS-OH surface: histograms represent relative scattering by 
intensity (a) and by number (b). Results shown are for: (13a) & (13b) after 90 minutes; 










































































































































































































Figure B.19. DLS analysis of bovine insulin (SIGMA, Cat. #: I5500 (lot 019K17765V) 
aggregation in the presence of PS-OH surface: histograms represent relative scattering by 
intensity (a) and by number (b). Results shown are for: (16a) & (16b) after 330 minutes; 






























































































































Figure B.20. DLS analysis of bovine insulin (SIGMA, Cat. #: I5500 (lot 019K17765V) 
aggregation in the presence of PS-COOH surface: histograms represent relative scattering 
by intensity (a) and by number (b). Results shown are for: (1a), (1b), (2a), (2b), (3a) & 








































































































































































































Figure B.21. DLS analysis of bovine insulin (SIGMA, Cat. #: I5500 (lot 019K17765V) 
aggregation in the presence of PS-COOH surface: histograms represent relative scattering 
by intensity (a) and by number (b). Results shown are for: (4a) & (4b) before incubation; 
(5a), (5b), (6a) & (6b) after 30 minutes of incubation. Sample (4) is the duplicate of 





























































































































































































Figure B.22. DLS analysis of bovine insulin (SIGMA, Cat. #: I5500 (lot 019K17765V) 
aggregation in the presence of PS-COOH surface: histograms represent relative scattering 
by intensity (a) and by number (b). Results shown are for: (7a), (7b), (8a) & (8b) after 45 











































































































































































































































Figure B.23. DLS analysis of bovine insulin (SIGMA, Cat. #: I5500 (lot 019K17765V) 
aggregation in the presence of PS-COOH surface: histograms represent relative scattering 
by intensity (a) and by number (b). Results shown are for: (10a) & (10b) after 60 
minutes; (11a) & (11b) after 90 minutes; and (12a) & (12b) after 150 minutes of 



















































































































































































































Figure B.24. DLS analysis of bovine insulin (SIGMA, Cat. #: I5500 (lot 019K17765V) 
aggregation in the presence of PS-COOH surface: histograms represent relative scattering 
by intensity (a) and by number (b). Results shown are for: (13a) & (13b) after 420 






























































Figure B.25. DLS analysis of bovine insulin (SIGMA, Cat. #: I5500 (lot 019K17765V) 
aggregation in the presence of PS-NH2 surface: histograms represent relative scattering 
by intensity (a) and by number (b). Results shown are for: (1a), (1b), (2a), (2b), (3a) & 


































































































































































































Figure B.26. DLS analysis of bovine insulin (SIGMA, Cat. #: I5500 (lot 019K17765V) 
aggregation in the presence of PS-NH2 surface: histograms represent relative scattering 
by intensity (a) and by number (b). Results shown are for: (4a) & (4b) before incubation; 
(5a), (5b), (6a) & (6b) after 30 minutes of incubation. Sample (4) is the duplicate of 





























































































































































































































Figure B.27. DLS analysis of bovine insulin (SIGMA, Cat. #: I5500 (lot 019K17765V) 
aggregation in the presence of PS-NH2 surface: histograms represent relative scattering 
by intensity (a) and by number (b). Results shown are for: (7a) & (7b) after 45 minutes; 
















































































































































































Figure B.28. DLS analysis of bovine insulin (SIGMA, Cat. #: I5500 (lot 019K17765V) 
aggregation in the presence of PS-NH2 surface: histograms represent relative scattering 
by intensity (a) and by number (b). Results shown are for: (10a), (10b), (11a) & (11b) 
after 90 minutes; and (12a) & (12b) after 120 minutes of incubation. Sample (11) is the 






































































































































































































Figure B.29. DLS analysis of bovine insulin (SIGMA, Cat. #: I5500 (lot 019K17765V) 
aggregation in the presence of PS-NH2 surface: histograms represent relative scattering 
by intensity (a) and by number (b). Results shown are for: (13a) & (13b) after 120 
minutes; (14a) & (14b) after 150 minutes; and (15a) & (15b) after 180 minutes of 


































































































































































































Figure B.30. DLS analysis of bovine insulin (SIGMA, Cat. #: I5500 (lot 019K17765V) 
aggregation in the presence of PS-NH2 surface: histograms represent relative scattering 
by intensity (a) and by number (b). Results shown are for: (16a) & (16b) after 180 
minutes; (17a), (17b), (18a) & (18b) after 210 minutes of incubation. Sample (16) is the 


















































































































































































































Figure B.31. DLS analysis of bovine insulin (SIGMA, Cat. #: I5500 (lot 019K17765V) 
aggregation in the presence of PS-NH2 surface: histograms represent relative scattering 
by intensity (a) and by number (b). Results shown are for: (19a) & (19b) after 240 

























































































































































































































Figure B.32. DLS analysis of bovine insulin (SIGMA, Cat. #: I5500 (lot 019K17765V) 
aggregation in the presence of PS-NH2 surface: histograms represent relative scattering 
by intensity (a) and by number (b). Results shown are for: (22a) & (22b) after 420 




































































DYNAMIC LIGHT SCATTERING HISTOGRAMS 
 
OF HUMAN ISULIN IN BULK AND IN THE PRESENCE OF POLYSTYRENE 
  











Figure C.1. DLS analysis of human insulin (SACF Biosciences, Cat. #: 91077 (lot 
10L917) aggregation in bulk: histograms represent relative scattering by intensity (a) and 
by number (b). Results shown are for: (1a) & (1b) before incubation; (2a), (2b)  25 












































































































































































Figure C.2. DLS analysis of human insulin (SACF Biosciences, Cat. #: 91077 (lot 
10L917)) aggregation in bulk: histograms represent relative scattering by intensity (a) 
and by number (b). Results shown are for: (4a) & (4b) 100 minutes; (5a), (5b) 110 






























































































































































Figure C.3. DLS analysis of human insulin (SACF Biosciences, Cat. #: 91077, lot 
10L917) aggregation in the presence of PS surface: histograms represent relative 
scattering by intensity (a) and by number (b). Results shown are for: (1a), (1b), (2a) & 
(2b) before incubation; and (3a) & (3b) 25 minutes of incubation. Sample (2) is the 












































































































































































































Figure C.4. DLS analysis of human insulin (SACF Biosciences, Cat. #: 91077, lot 
10L917) aggregation in the presence of PS surface: histograms represent relative 
scattering by intensity (a) and by number (b). Results shown are for: (4a) & (4b) 25 
minutes; and (5a), (5b), (6a) & (6b) 45 minutes of incubation. Sample (4) is the duplicate 


















































































































































































Figure C.5. DLS analysis of human insulin (SACF Biosciences, Cat. #: 91077, lot 
10L917) aggregation in the presence of PS surface: histograms represent relative 
scattering by intensity (a) and by number (b). Results shown are for: (7a), (7b), (8a) & 
































































































































































Figure C.6. DLS analysis of human insulin (SACF Biosciences, Cat. #: 91077, lot 
10L917) aggregation in the presence of PS surface: histograms represent relative 
scattering by intensity (a) and by number (b). Results shown are for: (10a) & (10b) 85 
minutes; and (11a), (11b), (12a) & (12b) 100 minutes of incubation. Sample (12) is the 




































































































































































Figure C.7. DLS analysis of human insulin (SACF Biosciences, Cat. #: 91077, lot 
10L917) aggregation in the presence of PS surface: histograms represent relative 
scattering by intensity (a) and by number (b). Results shown are for: (13a) & (13b) 110 




































































































Figure C.8. DLS analysis of human insulin (SACF Biosciences, Cat. #: 91077, lot 
10L917) aggregation in the presence of PS-OH surface: histograms represent relative 
scattering by intensity (a) and by number (b). Results shown are for: (1a), (1b), (2a) & 
(2b) before incubation; and (3a) & (3b) 25 minutes of incubation. Sample (2) is the 


















































































































































































































Figure C.9. DLS analysis of human insulin (SACF Biosciences, Cat. #: 91077, lot 
10L917) aggregation in the presence of PS-OH surface: histograms represent relative 
scattering by intensity (a) and by number (b). Results shown are for: (4a) & (4b) 25 
minutes; and (5a), (5b), (6a) & (6b) 45 minutes of incubation. Sample (4) is the duplicate 
















































































































































































Figure C.10. DLS analysis of human insulin (SACF Biosciences, Cat. #: 91077, lot 
10L917) aggregation in the presence of PS-OH surface: histograms represent relative 
scattering by intensity (a) and by number (b). Results shown are for: (7a), (7b), (8a) & 

























































































































Figure C.11. DLS analysis of human insulin (SACF Biosciences, Cat. #: 91077, lot 
10L917) aggregation in the presence of PS-COOH surface: histograms represent relative 
scattering by intensity (a) and by number (b). Results shown are for: (1a), (1b), (2a) & 
(2b) before incubation; and (3a) & (3b) 25 minutes of incubation. Sample (2) is the 


























































































































































Figure C.12. DLS analysis of human insulin (SACF Biosciences, Cat. #: 91077, lot 
10L917) aggregation in the presence of PS-COOH surface: histograms represent relative 
scattering by intensity (a) and by number (b). Results shown are for: (4a) & (4b) 25 
minutes; and (5a), (5b), (6a) & (6b) 45 minutes of incubation. Sample (4) is the duplicate 


























































































































































































































Figure C.13. DLS analysis of human insulin (SACF Biosciences, Cat. #: 91077, lot 
10L917) aggregation in the presence of PS-COOH surface: histograms represent relative 
scattering by intensity (a) and by number (b). Results shown are for: (7a), (7b), (8a) & 


































































































































































Figure C.14. DLS analysis of human insulin (SACF Biosciences, Cat. #: 91077, lot 
10L917) aggregation in the presence of PS-NH2 surface: histograms represent relative 
scattering by intensity (a) and by number (b). Results shown are for: (1a), (1b), (2a) & 
(2b) before incubation; and (3a) & (3b) 25 minutes of incubation. Sample (2) is the 










































































































































































Figure C.15. DLS analysis of human insulin (SACF Biosciences, Cat. #: 91077, lot 
10L917) aggregation in the presence of PS-NH2 surface: histograms represent relative 
scattering by intensity (a) and by number (b). Results shown are for: (4a) & (4b) 25 
minutes; and (5a), (5b), (6a) & (6b) 45 minutes of incubation. Sample (4) is the duplicate 










































































































































































































Figure C.16. DLS analysis of human insulin (SACF Biosciences, Cat. #: 91077, lot 
10L917) aggregation in the presence of PS-NH2 surface: histograms represent relative 
scattering by intensity (a) and by number (b). Results shown are for: (7a), (7b), (8a) & 




























































































































































































Figure C.17. DLS analysis of human insulin (SACF Biosciences, Cat. #: 91077, lot 
10L917) aggregation in the presence of PS-NH2 surface: histograms represent relative 
scattering by intensity (a) and by number (b). Results shown are for: (10a) & (10b) 100 


























































































DYNAMIC LIGHT SCATTERING HISTOGRAMS 
 
OF BOVINE INSULIN IN BULK AND IN THE PRESENCE OF LIPOSOMES  
 











Figure D.1. DLS analysis of bovine insulin (SIGMA, Cat. #: I5500 (lot 019K17765V) 
aggregation in bulk: histograms represent relative scattering by intensity (a) and by 
number (b). Results shown are for: (1a) & (1b) 30 minutes; (2a) & (2b) 60 minutes; and 










































































































































































































































Figure D.2. DLS analysis of bovine insulin (SIGMA, Cat. #: I5500 (lot 019K17765V) 
aggregation in bulk: histograms represent relative scattering by intensity (a) and by 
number (b). Results shown are for: (4a) & (4b) 150 minutes of incubation. Sample (4) is 































































































Figure D.3. DLS analysis of bovine insulin (SIGMA, Cat. #: I5500 (lot 019K17765V) 
aggregation in the presence of liposome 1 (80/20)%  PC/PS: histograms represent relative 
scattering by intensity (a) and by number (b). Results shown are for: (1a), (1b), (2a) & 


















































































































































































































Figure D.4. DLS analysis of bovine insulin (SIGMA, Cat. #: I5500 (lot 019K17765V) 
aggregation in the presence of liposome 1 (80/20)%  PC/PS: histograms represent relative 
scattering by intensity (a) and by number (b). Results shown are for: (4a) & (4b) 90 
minutes; (5a) & (5b) 120 minutes and (6a) & (6b) after 150 minutes of incubation. 

































































































































































































Figure D.5. DLS analysis of bovine insulin (SIGMA, Cat. #: I5500 (lot 019K17765V) 
aggregation in the presence of liposome 2 (20/80)%  PC/C: histograms represent relative 
scattering by intensity (a) and by number (b). Results shown are for: (1a), (1b), (2a) & 


























































































































































































































































Figure D.6. DLS analysis of bovine insulin (SIGMA, Cat. #: I5500 (lot 019K17765V) 
aggregation in the presence of liposome 2 (20/80)%  PC/C: histograms represent relative 
scattering by intensity (a) and by number (b). Results shown are for: (4a) & (4b) 90 
minutes; (5a), (5b), (6a) & (6b) after 150 minutes of incubation. Sample (4) is the 




















































































































































































Figure D.7. DLS analysis of bovine insulin (SIGMA, Cat. #: I5500 (lot 019K17765V) 
aggregation in the presence of liposome 2 (20/80)%  PC/C: histograms represent relative 
scattering by intensity (a) and by number (b). Results shown are for: (7a) & (7b) 180 





















































Figure D.8. DLS analysis of bovine insulin (SIGMA, Cat. #: I5500 (lot 019K17765V) 
aggregation in the presence of liposome 3 (80/20)%  PC/C: histograms represent relative 
scattering by intensity (a) and by number (b). Results shown are for: (1a), (1b), (2a) & 

































































































































































































































Figure D.9. DLS analysis of bovine insulin (SIGMA, Cat. #: I5500 (lot 019K17765V) 
aggregation in the presence of liposome 3 (80/20)%  PC/C: histograms represent relative 
scattering by intensity (a) and by number (b). Results shown are for: (4a), (4b), (5a) & 






















































































































































































Figure D.10. DLS analysis of bovine insulin (SIGMA, Cat. #: I5500 (lot 019K17765V) 
aggregation in the presence of liposome 4 (2:2:1:1) C/PC/PG/PE: histograms represent 
relative scattering by intensity (a) and by number (b). Results shown are for: (1a) & (1b) 
30 minutes; and (2a), (2b), (3a) & (3b) after 60 minutes of incubation. Sample (3) is the 












































































































































































































Figure D.11. DLS analysis of bovine insulin (SIGMA, Cat. #: I5500 (lot 019K17765V) 
aggregation in the presence of liposome 4 (2:2:1:1) C/PC/PG/PE: histograms represent 
relative scattering by intensity (a) and by number (b). Results shown are for: (4a) & (4b) 















































































































































































Figure D.12. DLS analysis of bovine insulin (SIGMA, Cat. #: I5500 (lot 019K17765V) 
aggregation in the presence of liposome 5 (10:5:7.5:16) PC/PE/PS/C: histograms 
represent relative scattering by intensity (a) and by number (b). Results shown are for: 
(1a) & (1b) 30 minutes; and (2a), (2b), (3a) & (3b) after 60 minutes of incubation. 




































































































































































































































































Figure D.13. DLS analysis of bovine insulin (SIGMA, Cat. #: I5500 (lot 019K17765V) 
aggregation in the presence of liposome 5 (10:5:7.5:16) PC/PE/PS/C: histograms 
represent relative scattering by intensity (a) and by number (b). Results shown are for: 










































































































































Figure E.1 Congo red results of bovine insulin in bulk and in the presence of surfaces:  
(CELL Applications, INC. Cat.  :128 -100 (lot 104), lyophilized): Blank (      ); Sample (- 
- -). (1) and (1d) are bovine insulin and its duplicate; (2) and (2d) are bovine insulin and 
its duplicate in liposome 2 (20/80)% PC/C; (3) and (3d) are bovine insulin and its 






























































































Figure E.2. Congo red results of bovine insulin in bulk and in the presence of surfaces:  
(CELL Applications, INC. Cat.  : 128 -100 (lot 104), lyophilized): Blank (      ); Sample 
(- - -). (4) and (4d) are bovine insulin and its duplicate in liposome 5 (10:5:7.5:16) 
PC/PE/PS/C; (5) and (5d) are bovine insulin and its duplicate in liposome  6 (50/50)% 





























































































Figure E.3. Congo red results of bovine insulin in bulk and in the presence of surfaces:  
(CELL Applications, INC. Cat. #: 128 -100 (lot 104), lyophilized): Blank (      ); Sample 







































Figure E.4 Congo red results of bovine insulin in bulk and in the presence of surfaces:  
(CELL Applications, INC. Cat. #: 128 -100 (lot 104), lyophilized): Blank (    ); Sample (- 
- -). (1) and (1d) are bovine insulin and its duplicate; (2) and (2d) are bovine insulin and 
its duplicate in liposome 2 (20/80)% PC/C; (3) and (3d) are bovine insulin and its 

































































































Figure E.5. Congo red results of bovine insulin in bulk and in the presence of surfaces:  
(CELL Applications, INC. Cat. #: 128 -100 (lot 104), lyophilized): Blank (    ); Sample (- 
- -). (4) and (4d) are bovine insulin and its duplicate in liposome 5 (10:5:7.5:16) 
PC/PE/PS/C; (5) and (5d) are bovine insulin and its duplicate in liposome  6 (50/50)% 




























































































Figure E.6. Congo red results of bovine insulin in bulk and in the presence of surfaces:  
(CELL Applications, INC. Cat. #:128-100 (lot 104), lyophilized): Blank (    ); Sample (- - 






































Figure E.7 Congo red results of human insulin in bulk and in the presence of surfaces  
(SACF Biosciences, Cat. #: 91077C-250MG (lot 10L917)): Blank (      ); Sample (- - -). 
(1) and (1d) are human insulin and its duplicate; (2) and (2d) are human insulin and its 
duplicate in liposome 2 (20/80)% PC/C; (3) and (3d) are human insulin and its duplicate 

































































































Figure E.8. Congo red results of human insulin in bulk and in the presence of surfaces  
(SACF Biosciences, Cat. #: 91077C-250MG (lot 10L917)): Blank (    ); Sample (- - -). (4) 
and (4d) are human insulin and its duplicate in liposome 5 (10:5:7.5:16) PC/PE/PS/C; (5) 
and (5d) are human insulin and its duplicate in liposome  6 (50/50)% PC/C; (6) and (6d) 




























































































Figure E.9. Congo red results of human insulin in bulk and in the presence of surfaces  
(SACF Biosciences, Cat. #: 91077C-250MG (lot 10L917)): Blank (      ); Sample (- - -). 


































HUMAN INSULIN INCUBATED FOR 55 HOURS AT 37 ˚C AND 230 RPM 
 
 
Figure E.10 Congo red results of human insulin in bulk and in the presence of surfaces 
(SIGMA I2643, lot (096K03811V)): Blank (    ); Sample (- - -). (1) and (1d) are human 
insulin and its duplicate; (2) and (2d) are human insulin and its duplicate in liposome 2 
































































































Figure E.11. Congo red results of human insulin in bulk and in the presence of surfaces: 
(SIGMA I2643, lot (096K03811V)): Blank (    ); Sample (- - -). (4) and (4d) are human 
insulin and its duplicate in liposome 5 (10:5:7.5:16) PC/PE/PS/C; (5) and (5d) are human 
insulin and its duplicate in liposome  6 (50/50)% PC/C; (6) and (6d) are human insulin 



























































































Figure E.12. Congo red results of human insulin in bulk and in the presence of surfaces: 
(SIGMA I2643, lot (096K03811V)): Blank (    ); Sample (- - -). (7) and (7d) are human 
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